<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library</title> <meta content="Antibiotics for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015254.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for otitis media with effusion (OME) in children - Mulvaney, CA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015254.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015254.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for otitis media with effusion (OME) in children" name="citation_title"/> <meta content="Caroline A Mulvaney" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Kevin Galbraith" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Katie E Webster" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Mridul Rana" name="citation_author"/> <meta content="Frimley Health NHS Foundation Trust" name="citation_author_institution"/> <meta content="Rachel Connolly" name="citation_author"/> <meta content="National Institute for Health and Care Excellence" name="citation_author_institution"/> <meta content="Tal Marom" name="citation_author"/> <meta content="Samson Assuta Ashdod University Hospital, Ben Gurion University Faculty of Health Sciences" name="citation_author_institution"/> <meta content="Mat Daniel" name="citation_author"/> <meta content="Nottingham Children's Hospital" name="citation_author_institution"/> <meta content="Roderick P Venekamp" name="citation_author"/> <meta content="University Medical Center Utrecht, Utrecht University" name="citation_author_institution"/> <meta content="Anne GM Schilder" name="citation_author"/> <meta content="Samuel MacKeith" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="samuel.mackeith@ouh.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD015254.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015254.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015254.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015254.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anaphylaxis [chemically induced, drug therapy]; Anti-Bacterial Agents [adverse effects]; *Hearing Loss [chemically induced, etiology]; *Otitis Media with Effusion [drug therapy]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015254.pub2&amp;doi=10.1002/14651858.CD015254.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015254\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015254\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015254.pub2",title:"Antibiotics for otitis media with effusion (OME) in children",firstPublishedDate:"Oct 23, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015254.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015254.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015254.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015254.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015254.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015254.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015254.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015254.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015254.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015254.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2487 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015254.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/appendices#CD015254-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/supinfo/CD015254-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/supinfo/CD015254-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for otitis media with effusion (OME) in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0004">Caroline A Mulvaney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0005">Kevin Galbraith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0006">Katie E Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0007">Mridul Rana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0008">Rachel Connolly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0009">Tal Marom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0010">Mat Daniel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0011">Roderick P Venekamp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0012">Anne GM Schilder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information#CD015254-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Samuel MacKeith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information/en#CD015254-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015254.pub2">https://doi.org/10.1002/14651858.CD015254.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015254-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015254-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015254-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015254-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015254-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015254-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015254-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015254-abs-0001" lang="en"> <section id="CD015254-sec-0001"> <h3 class="title" id="CD015254-sec-0001">Background</h3> <p>Otitis media with effusion (OME) is an accumulation of fluid in the middle ear cavity, common amongst young children. The fluid may cause hearing loss. When persistent, it may lead to developmental delay, social difficulty and poor quality of life. Management of OME includes watchful waiting, autoinflation, medical and surgical treatment. Antibiotics are sometimes used to treat any bacteria present in the effusion, or associated biofilms. </p> </section> <section id="CD015254-sec-0002"> <h3 class="title" id="CD015254-sec-0002">Objectives</h3> <p>To assess the effects (benefits and harms) of oral antibiotics for otitis media with effusion (OME) in children. </p> </section> <section id="CD015254-sec-0003"> <h3 class="title" id="CD015254-sec-0003">Search methods</h3> <p>The Cochrane ENT Information Specialist searched the Cochrane ENT Register, CENTRAL, Ovid MEDLINE, Ovid Embase, Web of Science, ClinicalTrials.gov, ICTRP and additional sources for published and unpublished studies to 20 January 2023. </p> </section> <section id="CD015254-sec-0004"> <h3 class="title" id="CD015254-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials and quasi‐randomised trials in children aged 6 months to 12 years with unilateral or bilateral OME. We included studies that compared oral antibiotics with either placebo or no treatment. </p> </section> <section id="CD015254-sec-0005"> <h3 class="title" id="CD015254-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were determined following a multi‐stakeholder prioritisation exercise and were: 1) hearing, 2) otitis media‐specific quality of life and 3) anaphylaxis. Secondary outcomes were: 1) persistence of OME, 2) adverse effects, 3) receptive language skills, 4) speech development, 5) cognitive development, 6) psychosocial skills, 7) listening skills, 8) generic health‐related quality of life, 9) parental stress, 10) vestibular function and 11) episodes of acute otitis media. We used GRADE to assess the certainty of evidence for each outcome. </p> <p>Although we included all measures of hearing assessment, the proportion of children who returned to normal hearing was our preferred method to assess hearing, due to challenges in interpreting the results of mean hearing thresholds. </p> </section> <section id="CD015254-sec-0006"> <h3 class="title" id="CD015254-sec-0006">Main results</h3> <p>We identified 19 completed studies that met our inclusion criteria (2581 participants). They assessed a variety of oral antibiotics (including penicillins, cephalosporins, macrolides and trimethoprim), with most studies using a 10‐ to 14‐day treatment course. We had some concerns about the risk of bias in all studies included in this review. Here we report our primary outcomes and main secondary outcome, at the longest reported follow‐up time. </p> <p><b>Antibiotics versus placebo</b> </p> <p>We included 11 studies for this comparison, but none reported all of our outcomes of interest and limited meta‐analysis was possible. </p> <p><i>Hearing</i> </p> <p>One study found that more children may return to normal hearing by two months (resolution of the air‐bone gap) after receiving antibiotics as compared with placebo, but the evidence is very uncertain (Peto odds ratio (OR) 9.59, 95% confidence interval (CI) 3.51 to 26.18; 20/49 children who received antibiotics returned to normal hearing versus 0/37 who received placebo; 1 study, 86 participants; very low‐certainty evidence). </p> <p><i>Disease‐specific quality of life</i> </p> <p>No studies assessed this outcome.</p> <p><i>Presence/persistence of OME</i> </p> <p>At 6 to 12 months of follow‐up, the use of antibiotics compared with placebo may slightly reduce the number of children with persistent OME, but the confidence intervals were wide, and the evidence is very uncertain (risk ratio (RR) 0.89, 95% CI 0.68 to 1.17; 48% versus 54%; number needed to treat (NNT) 17; 2 studies, 324 participants; very low‐certainty evidence). </p> <p><i>Adverse event: anaphylaxis</i> </p> <p>No studies provided specific data on anaphylaxis. Three of the included studies (448 children) did report adverse events in sufficient detail to assume that no anaphylactic reactions occurred, but the evidence is very uncertain (very low‐certainty evidence). </p> <p><b>Antibiotics versus no treatment</b> </p> <p>We included eight studies for this comparison, but very limited meta‐analysis was possible. </p> <p><i>Hearing</i> </p> <p>One study found that the use of antibiotics compared to no treatment may result in little to no difference in final hearing threshold at three months (mean difference (MD) ‐5.38 dB HL, 95% CI ‐9.12 to ‐1.64; 1 study, 73 participants; low‐certainty evidence). The only data identified on the return to normal hearing were reported at 10 days of follow‐up, which we considered to be too short to accurately reflect the efficacy of antibiotics. </p> <p><i>Disease‐specific quality of life</i> </p> <p>No studies assessed this outcome.</p> <p><i>Presence/persistence of OME</i> </p> <p>Antibiotics may reduce the proportion of children who have persistent OME at up to three months of follow‐up, when compared with no treatment (RR 0.64, 95% CI 0.50 to 0.80; 6 studies, 542 participants; low‐certainty evidence). </p> <p><i>Adverse event: anaphylaxis</i> </p> <p>No studies provided specific data on anaphylaxis. Two of the included studies (180 children) did report adverse events in sufficient detail to assume that no anaphylactic reactions occurred, but the evidence is very uncertain (very low‐certainty evidence). </p> </section> <section id="CD015254-sec-0007"> <h3 class="title" id="CD015254-sec-0007">Authors' conclusions</h3> <p>The evidence for the use of antibiotics for OME is of low to very low certainty. Although the use of antibiotics compared to no treatment may have a slight beneficial effect on the resolution of OME at up to three months, the overall impact on hearing is very uncertain. The long‐term effects of antibiotics are unclear and few of the studies included in this review reported on potential harms. These important endpoints should be considered when weighing up the potential short‐ and long‐term benefits and harms of antibiotic treatment in a condition with a high spontaneous resolution rate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015254-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015254-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015254-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015254-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015254-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015254-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015254-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015254-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD015254-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015254-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015254-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015254-abs-0002" lang="en"> <h3>Antibiotics for otitis media with effusion (OME or 'glue ear') in children</h3> <p><b>Key messages</b> </p> <p>We are uncertain whether the use of antibiotics improves hearing for children with glue ear, due to a lack of robust evidence. </p> <p>The use of antibiotics compared to no treatment might slightly reduce the number of children who have glue ear at three months of follow‐up. It is unclear whether this is a long‐lasting effect, as few studies followed up children for more than three months. </p> <p>The studies included in this review did not report serious harms from treatment with antibiotics. However, there is some suggestion that antibiotics may cause unpleasant side effects such as skin rash. </p> <p><b>What is OME?</b> </p> <p>Glue ear (or 'otitis media with effusion', OME) is a relatively common condition affecting young children. Fluid collects in the middle ear, which may cause hearing impairment. As a result of their poor hearing, children may be behind in their speech and may have difficulties at school. </p> <p><b>How is OME treated?</b> </p> <p>Most of the time OME does not need any treatment and the symptoms will get better with time. In children with persistent OME, different treatments have been used, including medications or surgery (insertion of grommets (ventilation tubes), with or without adenoidectomy). Sometimes, bacteria are present in the fluid that collects in the middle ear. Antibiotics are sometimes used to try and get rid of these bacteria, and improve the symptoms of OME. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to identify whether antibiotics are better than placebo (sham or dummy treatment), or no treatment, for children with OME. </p> <p>We also wanted to see whether there are any unwanted effects associated with taking antibiotics for this condition. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared oral antibiotic treatment with either placebo or no treatment in children with OME. We compared and summarised the study results, and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We included 19 studies involving over 2500 children. Many different types of oral antibiotics were used and the duration of treatment varied a lot between the studies. </p> <p>It is unclear whether antibiotics have any effect on hearing, as the evidence was not robust. </p> <p>When compared to no treatment, antibiotics might slightly reduce the number of children who have OME after three months of follow‐up. Only two studies looked at the number of children with OME after a longer follow‐up time, so we are uncertain whether this is a long‐lasting effect, as OME may recur. </p> <p>We do not know if treatment with antibiotics has any effect on quality of life as none of the studies included in this review assessed this outcome. We were unable to find much evidence on the occurrence of anaphylaxis ‐ a rare but very serious allergic reaction. None of the studies reported that any children suffered from anaphylaxis, but this may be because no one had a reaction, or simply because the studies did not report this. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>As the evidence included in this Cochrane Review was uncertain, we cannot be sure if treatment with antibiotics gives any benefit to children with OME. As most of the studies were very short in duration, we do not know if any effect of antibiotics would continue over longer time periods ‐ even if OME appears to get better in the short term, it may recur. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date to January 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015254-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015254-sec-0119"></div> <h3 class="title" id="CD015254-sec-0120">Implications for practice</h3> <section id="CD015254-sec-0120"> <p>The use of antibiotics compared to no treatment may slightly reduce the proportion of children with otitis media with effusion (OME) at up to three months of follow‐up. However, the overall impact of antibiotics on hearing is very uncertain. Adverse effects were poorly reported in the studies included in this review; however, it is worth noting that antibiotics may be associated with potentially harmful effects (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>). In addition, consideration should be given to antibiotic stewardship ‐ particularly where benefits from treatment are uncertain. </p> </section> <h3 class="title" id="CD015254-sec-0121">Implications for research</h3> <section id="CD015254-sec-0121"> <p>This review forms part of a suite of five reviews that consider interventions for OME (<a href="./references#CD015254-bbs2-0073" title="GalbraithK , MulvaneyCA , MacKeithS , MaromT , DanielM , VenekampRP , et al. Autoinflation for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015253. [DOI: 10.1002/14651858.CD015253]">Galbraith 2022</a>; <a href="./references#CD015254-bbs2-0087" title="MacKeithS , MulvaneyCA , GalbraithK , MaromT , DanielM , VenekampRP , et al. Adenoidectomy for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015252. [DOI: 10.1002/14651858.CD015252]">MacKeith 2022a</a>; <a href="./references#CD015254-bbs2-0088" title="MacKeithS , MulvaneyCA , GalbraithK , MaromT , DanielM , VenekampRP , et al. Ventilation tubes (grommets) for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015215. [DOI: 10.1002/14651858.CD015215]">MacKeith 2022b</a>; <a href="./references#CD015254-bbs2-0094" title="MulvaneyCA , GalbraithK , MacKeithS , MaromT , DanielM , VenekampRP , et al. Topical and oral steroids for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015255. [DOI: 10.1002/14651858.CD015255]">Mulvaney 2022a</a>; <a href="./references#CD015254-bbs2-0118" title="MulvaneyCA , GalbraithK , MacKeithS , MaromT , DanielM , VenekampRP , et al. Antibiotics for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews2022, Issue 4. Art. No: CD015254. [DOI: 10.1002/14651858.CD015254]">Mulvaney 2022b</a>). Here we present implications for research in this field, which are shared across the suite of reviews: </p> <p> <ul id="CD015254-list-0047"> <li> <p>As OME is a fluctuating condition with high rates of resolution and recurrence, and a highly variable impact on children, clinical trials (and, in particular, randomised controlled trials) may not be the research design of choice. Instead, evidence may be better obtained from surgical or clinical registries (for example, see <a href="./references#CD015254-bbs2-0109" title="SchmalbachCE , BreretonJ , BowmanC , Denneny IIIJC . American Academy of Otolaryngology–Head and Neck Surgery/Foundation Reg-ent Registry: Purpose, Properties, and Priorities. Otolaryngology–Head and Neck Surgery2021;164(5):964-71.">Schmalbach 2021</a>) or prospective cohort studies, with the use of 'big data'. These data sets may also be used to help identify subgroups of children who are at greater risk of persistent disease or long‐term consequences of OME. A clearer understanding of possible subgroups of children is needed to better target interventions to those who need them most, whilst avoiding over‐treatment for those in whom spontaneous resolution is anticipated. </p> </li> <li> <p>Adverse effects of interventions are important and should always be assessed. However, randomised controlled trials are also not the best method to consider these, especially when events are rare. Observational studies with longer follow‐up and larger numbers of participants are needed to provide more robust evidence on the frequency of side effects. It is important to note that the protocol, inclusion criteria and search strategy used for this review would have excluded these types of studies. It is therefore possible that evidence of this type may exist. With this in mind, we would advocate a review of observational data, to assess whether evidence regarding longer‐term outcomes and adverse events is already available. This may be particularly important when assessing harms from serious but rare adverse events. </p> </li> <li> <p>It is encouraging that a core outcome set has been developed in this field (<a href="./references#CD015254-bbs2-0066" title="BruceI , HarmanN , WilliamsonP , TierneyS , CalleryP , MohiuddinS , et al. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment2015;19(68):1-374. [DOI: 10.3310/hta19680]">Bruce 2015</a>; <a href="./references#CD015254-bbs2-0086" title="LiuPZ , Ismail-KochH , StephensonK , DonneAJ , FergieN , DerryJ , et al. A core outcome set for research on the management of otitis media with effusion in otherwise-healthy children. International Journal of Pediatric Otorhinolaryngology2020;134:110029. [DOI: 10.1016/j.ijporl.2020.110029]">Liu 2020</a>). Guidance on <i>how</i> to measure the different outcomes would also be helpful for future research. </p> </li> <li> <p>Comparison of mean hearing thresholds is widely used in research to assess the impact of different interventions on hearing. However, this outcome measure risks underestimating the potential impact of interventions on hearing. Small changes in mean hearing thresholds may be consistent with a substantial improvement in the number of children whose hearing returns to normal ‐ particularly in a condition with a high spontaneous resolution rate. We would encourage researchers to assess hearing with the proportion of children in whom hearing returns to normal, in preference to mean hearing thresholds. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015254-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015254-sec-0008"></div> <div class="table" id="CD015254-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antibiotics compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children (aged 6 months to 12 years) with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral antibiotics <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral antibiotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Hearing ‐ return to normal hearing</b> (as complete improvement in air‐bone gap in the worst ear) </p> <p>Follow‐up: 2 months (short‐term)</p> <p>№ of participants: 86<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>Peto OR 9.59<br/>(3.51 to 26.18) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Lower‐risk population*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>The evidence is very uncertain about the effect of antibiotics on return to normal hearing at 2 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5%<br/>(15.6 to 57.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.5% more<br/>(10.6 more to 52.9 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Moderate‐risk population*</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.2%<br/>(30.3 to 76.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2% more<br/>(19.3 more to 65.4 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Higher‐risk population*</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9%<br/>(38.2 to 82.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9% more<br/>(23.2 more to 67.2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease‐specific quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No evidence was identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Presence/persistence of OME</b> </p> <p>Follow‐up: range 6 months to 12 months (medium‐term)</p> <p>№ of participants: 324 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.68 to 1.17) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of antibiotics on persistence of OME at 6 to 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1%<br/>(36.7 to 63.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9% fewer<br/>(17.3 fewer to 9.2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event: anaphylaxis</b> </p> <p>Follow‐up: range 3 weeks to 12 months</p> <p>№ of participants: 244 (3 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Three trials that did not report the incidence of anaphylaxis directly did, however, provide sufficient information to reasonably assume there were no such cases. One trial reported that there were no unwanted side effects from the drug (antibiotic) itself (<a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>); one trial did not list anaphylaxis amongst adverse events that were reported as "probably or possibly related to active treatment" (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>); and one trial reported that "no infant was withdrawn as a result of direct adverse reaction due to medication" (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of anaphylaxis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where there were zero events in the comparison group, the assumed risk in the comparison group was imputed from the same outcome comparing antibiotic with no treatment (<a href="./full#CD015254-tbl-0002">summary of findings Table 2</a>). This value was assumed to represent a 'moderate' control group event rate (CER), and values roughly 50% lower and higher are presented as 'lower' and 'higher' CERs respectively. </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for risk of performance detection and attrition bias. Downgraded by one level for imprecision as the optimal information size was not reached (&lt; 300 events). </p> <p><sup>2</sup>Downgraded by one level for risk of bias, due to the potential for underestimating the prevalence of OME at six months. Participants with two normal examinations at &lt; 6 months were not re‐assessed, but were considered to have resolution of OME. Downgraded by one level for inconsistency, as the studies showed opposite directions of effect. Downgraded by one level for indirectness, as a high‐risk population of children aged &lt; 12 months contributed most of the weight in the analysis. Downgraded by one level for serious imprecision, as the optimal information size was not reached (&lt; 300 events) and one decision threshold was crossed by the confidence interval (RR 0.80). </p> <p><sup>3</sup>Downgraded by three levels for extremely serious imprecision, as this was a narrative synthesis with zero events amongst 244 participants. We are unable to provide an estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015254-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antibiotics compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children (aged 6 months to 12 years) with otitis media with effusion (OME) <br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral antibiotics <br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without oral antibiotic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral antibiotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hearing ‐ hearing threshold</b><sup>‡</sup> (3 months; short‐term) </p> <p>№ of participants: 73 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final hearing threshold was 14.1 dB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.38 dB lower<br/>(9.12 lower to 1.64 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that antibiotics result in little to no difference in hearing threshold at 3 months when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No evidence was identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence/persistence of OME</b> (up to 3 months) </p> <p>№ of participants: 542 (6 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.50 to 0.80) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9%</p> <p>(43.7 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5% fewer (from 43.7 fewer to 17.5 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics may reduce the proportion of children with persistent OME at up to 3 months when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event: anaphylaxis</b> </p> <p>Follow‐up: range 2 months to 3 months</p> <p>№ of participants: 88 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without referring directly to anaphylaxis, two studies reported that no participants experienced adverse effects (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>). It is unlikely, therefore, that any participants experienced anaphylaxis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of anaphylaxis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>‡</sup>Note that additional data were available for the outcome 'Hearing ‐ return to normal hearing'. However, as the follow‐up duration was extremely short (10 days), we did not consider it meaningful to present these data in the summary of findings table. </p> <p><sup>1</sup>Downgraded by one level for a risk of performance bias. Downgraded by one level for serious imprecision as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>2</sup>Downgraded by two levels for risk of performance and detection bias. Not downgraded for imprecision, as there was a common direction of effect, despite some inconsistency (I<sup>2</sup> = 72%). </p> <p><sup>3</sup>Downgraded by three levels for extremely serious imprecision, as this was a narrative synthesis with no events reported amongst only 88 children. No estimate of effect size could be calculated. We did not downgrade for risk of bias, as this is an objective outcome, unlikely to be influenced by performance bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015254-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015254-sec-0009"></div> <section id="CD015254-sec-0010"> <h3 class="title" id="CD015254-sec-0010">Description of the condition</h3> <p>Otitis media with effusion (OME) is a common condition in early childhood. The condition, also known as 'glue ear' and serous otitis media, is defined as "the presence of fluid in the middle ear without signs or symptoms of acute infection" (<a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a>). </p> <p>A key clinical feature of OME is hearing loss, due to decreased mobility of the tympanic membrane and consequent loss of sound conduction (<a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a>). When hearing loss persists, this may affect speech and language development, and lead to behavioural problems in some children (<a href="./references#CD015254-bbs2-0095" title="National Institute for Health and Care Excellence. Otitis media with effusion in under 12s: surgery. Clinical guideline [CG60]. Published: 27 February 2008. https://www.nice.org.uk/guidance/cg60.">NICE 2008</a>). Other symptoms that may be attributable to OME include balance (vestibular) problems and ear discomfort (<a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a>). When symptoms persist, they may lead to poor school performance and affect a child's daily activities, social interactions and emotions, possibly leading to a poorer quality of life for the child (<a href="./references#CD015254-bbs2-0104" title="RosenfeldRM , BhayaMH , BowerCM , BrookhouserPE , CasselbrantML , ChanKH , et al. Impact of tympanostomy tubes on child quality of life. Archives of Otolaryngology--Head &amp; Neck Surgery2000;126:585-92.">Rosenfeld 2000</a>). </p> <p>It is thought that up to 80% of children have had OME by the age of four years, but a decline in prevalence is observed for children beyond six years of age (<a href="./references#CD015254-bbs2-0115" title="WilliamsonI . Otitis media with effusion in children. BMJ Clinical Evidence2011;2011:0502. [PMID: 21477396]">Williamson 2011</a>). Most episodes of OME in children resolve spontaneously within three months, however approximately 35% of children will have more than one episode of OME and, furthermore, 5% to 10% of episodes will last for more than a year (<a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a>). Children with OME following an episode of untreated AOM have a 59% rate of resolution by one month, rising to 74% by three months, while children with newly diagnosed OME of unknown duration demonstrate a resolution rate of 28% by three months and up to 42% by six months (<a href="./references#CD015254-bbs2-0105" title="RosenfeldRM , KayD . Natural history of untreated otitis media. Laryngoscope2003;113:1645-57. [DOI: 10.1097/00005537-200310000-00004]">Rosenfeld 2003</a>). The condition is more prevalent in children with Down syndrome or cleft palate (<a href="./references#CD015254-bbs2-0072" title="FlynnT , MöllerC , JönssonR , Lohmander A. The high prevalence of otitis media with effusion in children with cleft lip and palate as compared to children without clefts. International Journal of Pediatric Otorhinolaryngology2009;73:1441-6. [DOI: 10.1016/j.ijporl.2009.07.015]">Flynn 2009</a>; <a href="./references#CD015254-bbs2-0089" title="MarisM , WojciechowskiM , Van de HeyningP , BoudewynsA . A cross-sectional analysis of otitis media with effusion in children with Down syndrome. European Journal of Pediatrics2014;173:1319-25. [DOI: 10.1007/s00431-014-2323-5]">Maris 2014</a>). Atopy has been considered a potential risk factor for OME in children (<a href="./references#CD015254-bbs2-0082" title="Kreiner-MøllerE , ChawesBL , Caye-ThomasenP , BønnelykkeK , BisgaardH . Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clinical and Experimental Allergy2012;42(11):1615-20. [DOI: 10.1111/j.1365-2222.2012.04038.x]">Kreiner‐Møller 2012</a>; <a href="./references#CD015254-bbs2-0090" title="MarsegliaGL , PagellaF , CaimmiD , CaimmiS , CastellazziAM , PoddigheD , et al. Increased risk of otitis media with effusion in allergic children presenting with adenoiditis. Otolaryngology – Head and Neck Surgery2008;138(5):572-5. [DOI: 10.1016/j.otohns.2008.01.020]">Marseglia 2008</a>; <a href="./references#CD015254-bbs2-0116" title="ZernottiME , PawankarR , AnsoteguiI , BadellinoH , CroceJS , HossnyE , et al. Otitis media with effusion and atopy: is there a causal relationship?World Allergy Organization Journal2017;10(1):37. [DOI: 10.1186/s40413-017-0168-x]">Zernotti 2017</a>). </p> <p>Diagnosis of OME is typically by clinical examination including (pneumatic) otoscopy and/or tympanometry in primary care. Following diagnosis, there will often be a period of active observation, for at least three months. During the observation period the care provider may offer a non‐surgical intervention such as hearing aids or autoinflation. The National Institute for Health and Care Excellence (NICE) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO‐HNS) do not currently recommend the use of antibiotics, antihistamines, decongestants or corticosteroids for OME as there is insufficient evidence to suggest that they are effective treatments (<a href="./references#CD015254-bbs2-0095" title="National Institute for Health and Care Excellence. Otitis media with effusion in under 12s: surgery. Clinical guideline [CG60]. Published: 27 February 2008. https://www.nice.org.uk/guidance/cg60.">NICE 2008</a>; <a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a>). If OME has not resolved within the three‐month observation period, the child may be referred for further management/active intervention. This may include hearing aid provision or review by an ENT surgeon for consideration for myringotomy, ventilation tubes insertion and/or adenoidectomy. The choice of active intervention varies considerably. Earlier active intervention may be considered for children at increased risk of developmental difficulties (see <a href="./references#CD015254-bbs2-0106" title="RosenfeldRM , ShinJJ , SchwartzSR , CogginsR , GagnonL , HackellJM , et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology - Head &amp; Neck Surgery2016;154(1 Suppl):S1-S41.">Rosenfeld 2016</a> for a list of 'at‐risk' factors). </p> <p>This Cochrane Review focusses on antibiotics as a treatment for OME in children. This review forms part of a suite of five reviews of OME treatment, which will address those interventions identified in a prioritisation exercise as being most important and in need of up‐to‐date Cochrane Reviews, namely ventilation tubes, adenoidectomy with or without ventilation tubes, autoinflation, topical and oral steroids, and antibiotics (<a href="./references#CD015254-bbs2-0068" title="CochraneENT . Otitis media with effusion: a project to prioritise Cochrane systematic reviews. https://ent.cochrane.org/otitis-media-effusion-ome-glue-ear 2020 (accessed 3 November 2021).">Cochrane ENT 2020</a>). </p> </section> <section id="CD015254-sec-0011"> <h3 class="title" id="CD015254-sec-0011">Description of the intervention</h3> <p>The rationale for using antibiotics is to treat the bacteria that are identified in the middle ear fluid of approximately one‐third of children with OME (<a href="./references#CD015254-bbs2-0098" title="Park C-W, Han J-H, Jeong J-H, Cho S-H, Kang M-J, TaeK , et al. Detection rates of bacteria in chronic otitis media with effusion in children. Journal of Korean Medical Science2004;19:735-8. [DOI: 10.3346/jkms.2004.19.5.735]">Park 2004</a>; <a href="./references#CD015254-bbs2-0099" title="PoetkerDM , LindstromDR , EdmistonCE , KrepelCJ , LinkTR , KerschnerJE . Microbiology of middle ear effusions from 292 patients undergoing tympanostomy tube placement for middle ear disease. International Journal of Pediatric Otorhinolaryngology2005;69(6):799-804. [DOI: 10.1016/j.ijporl.2005.01.012]">Poetker 2005</a>), and/or bacterial biofilms that are present even more frequently (<a href="./references#CD015254-bbs2-0069" title="DanielM , Imtiaz-UmerS , FergieN , BirchallJP , BaystonR . Bacterial involvement in otitis media with effusion. International Journal of Pediatric Otorhinolaryngology2012;76:1416-22. [DOI: 10.1016/j.ijporl.2012.06.013]">Daniel 2012</a>). Studies of oral antibiotics of any type and duration will be included in this review. </p> </section> <section id="CD015254-sec-0012"> <h3 class="title" id="CD015254-sec-0012">How the intervention might work</h3> <p>A bacterial pathogen has been identified in the middle ear fluid of approximately a third of all children with OME (<a href="./references#CD015254-bbs2-0099" title="PoetkerDM , LindstromDR , EdmistonCE , KrepelCJ , LinkTR , KerschnerJE . Microbiology of middle ear effusions from 292 patients undergoing tympanostomy tube placement for middle ear disease. International Journal of Pediatric Otorhinolaryngology2005;69(6):799-804. [DOI: 10.1016/j.ijporl.2005.01.012]">Poetker 2005</a>), and bacterial biofilms have been implicated in the aetiology of OME (<a href="./references#CD015254-bbs2-0069" title="DanielM , Imtiaz-UmerS , FergieN , BirchallJP , BaystonR . Bacterial involvement in otitis media with effusion. International Journal of Pediatric Otorhinolaryngology2012;76:1416-22. [DOI: 10.1016/j.ijporl.2012.06.013]">Daniel 2012</a>; <a href="./references#CD015254-bbs2-0110" title="SeppanenE , ThorntonR , NorthH , CorscaddenKJ , WiertsemaS , VijayasekaranS , et al. Bacterial reservoirs in the middle ear of otitis-prone children are associated with repeat ventilation tube insertion. Pediatric Infectious Disease Journal2020;39(2):91-6. [DOI: 10.1097/INF.0000000000002541]">Seppanen 2020</a>), thus treatment of the infection by antibiotics offers a promising non‐surgical intervention. If antibiotics successfully eliminate the bacteria, this may more speedily resolve the problem of middle ear fluid and its sequelae observed in children with OME (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>). However, not all cases of OME are of bacterial origin and thus the potential benefits of antibiotics must be weighed against the adverse effects of antibiotics and possible risk of bacterial resistance (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>). </p> </section> <section id="CD015254-sec-0013"> <h3 class="title" id="CD015254-sec-0013">Why it is important to do this review</h3> <p>A Cochrane Review assessing the use of antibiotics to treat OME in children was published in 2016 (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>). The review excluded children with pre‐existing or past ventilation tubes, cleft palate or Down syndrome and included 25 randomised controlled trials (RCTs). The Cochrane authors concluded that oral antibiotics are associated with an increased chance of complete resolution of OME at two to three months post‐randomisation (moderate‐certainty evidence). However, there was a higher incidence of adverse effects associated with antibiotics, such as diarrhoea, vomiting or skin rash. The review authors found uncertain evidence for improvements in short‐term hearing, and did not find evidence that children treated with antibiotics had fewer ventilation tube insertions. They found no data on outcomes such as speech, language and cognitive development, or quality of life. </p> <p>A scoping search undertaken in 2020 identified three abstracts of studies of antibiotics for OME published since the Cochrane Review (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>), although these do not appear to be RCTs. A prioritisation exercise undertaken in 2020 identified a review of antibiotics for OME in children as a top priority (<a href="./references#CD015254-bbs2-0068" title="CochraneENT . Otitis media with effusion: a project to prioritise Cochrane systematic reviews. https://ent.cochrane.org/otitis-media-effusion-ome-glue-ear 2020 (accessed 3 November 2021).">Cochrane ENT 2020</a>). Given the potentially promising findings of the Cochrane Review and the recommendations by international guidelines against the use of antibiotics to treat OME in children, it is timely to update the evidence. </p> <p>This review has been produced as part of a suite of reviews, which also inform a NICE guideline on the management of OME in children (<a href="./references#CD015254-bbs2-0096" title="National Institute for Health and Care Excellence. Otitis media with effusion in under 12s. NICE guideline [NG233]. Published: 30 August 2023. https://www.nice.org.uk/guidance/ng233.">NICE 2023</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015254-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015254-sec-0014"></div> <p>To assess the effects (benefits and harms) of oral antibiotics for otitis media with effusion (OME) in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015254-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015254-sec-0015"></div> <section id="CD015254-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015254-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐randomised trials (where trials were designed as RCTs, but the sequence generation for allocation of treatment used methods such as alternative allocation, birth dates or alphabetical order). We included studies that randomised by participant or by cluster. </p> </section> <section id="CD015254-sec-0018"> <h4 class="title">Types of participants</h4> <p>The population of interest is children aged 6 months to 12 years with unilateral or bilateral otitis media with effusion. If a study included children aged younger than 6 months and older than 12 years, we only included the study if the majority of children fitted our inclusion criteria, or if the authors presented outcome data by age group. We included all children regardless of any comorbidity, such as Down syndrome or cleft palate. The clinical diagnosis of OME was confirmed by oto(micro)scopy or tympanometry, or both. </p> </section> <section id="CD015254-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD015254-sec-0020"> <h5 class="title">Interventions</h5> <p>Oral antibiotics of all types and courses of duration.</p> </section> <section id="CD015254-sec-0021"> <h5 class="title">Comparators</h5> <p>We were interested in the following two comparisons:</p> <p> <ul id="CD015254-list-0001"> <li> <p>oral antibiotics versus placebo;</p> </li> <li> <p>oral antibiotics versus no treatment.</p> </li> </ul> </p> <p>If study participants received other treatments, for example intranasal steroids, oral steroids, mucolytics or decongestants, we included these studies if both arms received identical treatment. </p> <p>We excluded studies in which one antibiotic was compared with another, or studies comparing one dose of an antibiotic to a different dose of the same antibiotic. </p> </section> </section> <section id="CD015254-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the following outcomes in the review, but we did not use them as a basis for including or excluding studies. We assessed all outcomes at very short term (&lt; 6 weeks for adverse events), short term (≤ 3 months), medium term (&gt; 3 months to ≤ 1 year) and long term (&gt; 1 year). </p> <section id="CD015254-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD015254-list-0002"> <li> <p>Hearing:</p> <ul id="CD015254-list-0003"> <li> <p>Proportion of children whose hearing has returned to normal, with normal hearing defined as 20 dB HL or less (assessed using age‐appropriate tests). </p> </li> <li> <p>Hearing threshold.</p> </li> </ul> </li> </ul> </p> <p>It was anticipated that study data for these outcomes may be derived from a variety of assessment methods. To avoid loss of important evidence, we extracted all such data for analysis. However, we gave consideration to the appropriateness of pooling different types of data in meta‐analysis. Our selection of primary outcomes was based principally upon clinical importance, but also permitted applicability across a variety of age‐appropriate assessment methods and considered the types of outcome data that are most likely to be available. Accordingly, we regard the proportion of participants whose hearing has returned to normal as the most important measure of hearing impact. We considered medium‐ and long‐term outcome data as the most clinically important. </p> <p> <ul id="CD015254-list-0004"> <li> <p>Disease‐specific quality of life measured using a validated instrument, for example:</p> <ul id="CD015254-list-0005"> <li> <p>OM8‐30 (<a href="./references#CD015254-bbs2-0077" title="HaggardMP , SmithSC , NichollsEE . Quality of life and child behaviour. In: RosenfeldRM , BluestoneCD , editors(s). Evidence-Based Otitis Media. 2nd edition. Hamilton, Ontario: BC Decker Inc, 2003:401-29. [https://researchonline.lshtm.ac.uk/id/eprint/15108]">Haggard 2003</a>); </p> </li> <li> <p>Otitis Media‐6 (<a href="./references#CD015254-bbs2-0103" title="RosenfeldRM , GoldsmithAJ , TetlusL , BalzanoA . Quality of life for children with otitis media. Archives of Otolaryngology--Head &amp; Neck Surgery1997;123:1049-54. [DOI: 10.1001/archotol.1997.01900100019002]">Rosenfeld 1997</a>). </p> </li> </ul> </li> <li> <p>Adverse events ‐ anaphylactic reaction.</p> </li> </ul> </p> </section> <section id="CD015254-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD015254-list-0006"> <li> <p>Presence/persistence of OME.</p> </li> <li> <p>Adverse events ‐ measured by the number of participants affected.</p> <ul id="CD015254-list-0007"> <li> <p>Tympanic membrane changes, such as:</p> <ul id="CD015254-list-0008"> <li> <p>atrophy;</p> </li> <li> <p>atelectasis or retraction;</p> </li> <li> <p>persistent perforation;</p> </li> <li> <p>myringosclerosis;</p> </li> <li> <p>tympanosclerosis.</p> </li> </ul> </li> <li> <p>Patient‐related, such as:</p> <ul id="CD015254-list-0009"> <li> <p>vomiting;</p> </li> <li> <p>diarrhoea;</p> </li> <li> <p>dry throat;</p> </li> <li> <p>nasal stinging;</p> </li> <li> <p>cough;</p> </li> <li> <p>long‐term hearing loss;</p> </li> <li> <p>postsurgical haemorrhage;</p> </li> <li> <p>pain.</p> </li> </ul> </li> </ul> </li> <li> <p>Receptive language skills, measured using a validated scale, for example:</p> <ul id="CD015254-list-0010"> <li> <p>Peabody Picture Vocabulary Test ‐ Revised (<a href="./references#CD015254-bbs2-0070" title="DunnLM , DunnDM . Peabody Picture Vocabulary Test (PPVT™-4). 4th edition. Pearson Education, 2007.">Dunn 2007</a>); </p> </li> <li> <p>relevant domains of the Reynell Developmental Language Scales (<a href="./references#CD015254-bbs2-0102" title="ReynellJH . Reynell Development Language Scales Manual. Windsor, UK: NFER-NELSON, 1985.">Reynell 1985</a>); </p> </li> <li> <p>relevant domains of the Preschool Language Scale (PLS) (<a href="./references#CD015254-bbs2-0117" title="ZimmermanIL , SteinerVG , PondRE . Preschool Language Scale-3. San Antonio, TX: The Psychological Corporation, 1992.">Zimmerman 1992</a>); </p> </li> <li> <p>relevant domains of the Sequenced Inventory of Communication (SCID) (<a href="./references#CD015254-bbs2-0079" title="HedrickDL , PratherEM , TobinAR . Sequenced Inventory of Communication Development. Seattle, WA: University of Washington Press, 1984.">Hedrick 1984</a>). </p> </li> </ul> </li> <li> <p>Speech development, or expressive language skills, measured using a validated scale, for example: </p> <ul id="CD015254-list-0011"> <li> <p>Schlichting test (<a href="./references#CD015254-bbs2-0108" title="SchlichtingJEPT , Lutje SpelbergHC . Schlichting Test for Language Comprehension; Instruction Manual. Woooden: Bohn Stafleu van Loghum, 2010.">Schlichting 2010</a>); </p> </li> <li> <p>Lexi list (<a href="./references#CD015254-bbs2-0107" title="SchlichtingJEPT , Lutje SpelbergHC . Lexilijst Begrip: an instrument to investigate language comprehension in children aged 15-25 months in the context of early identification. Amsterdam: Pearson Assessment &amp; Information BV, 2007.">Schlichting 2007</a>); </p> </li> <li> <p>relevant domains of the Reynell Developmental Language Scales (<a href="./references#CD015254-bbs2-0102" title="ReynellJH . Reynell Development Language Scales Manual. Windsor, UK: NFER-NELSON, 1985.">Reynell 1985</a>); </p> </li> <li> <p>relevant domains of the PLS (<a href="./references#CD015254-bbs2-0117" title="ZimmermanIL , SteinerVG , PondRE . Preschool Language Scale-3. San Antonio, TX: The Psychological Corporation, 1992.">Zimmerman 1992</a>); </p> </li> <li> <p>relevant domains of the SCID (<a href="./references#CD015254-bbs2-0079" title="HedrickDL , PratherEM , TobinAR . Sequenced Inventory of Communication Development. Seattle, WA: University of Washington Press, 1984.">Hedrick 1984</a>). </p> </li> </ul> </li> <li> <p>Cognitive development, measured using a validated scale, for example:</p> <ul id="CD015254-list-0012"> <li> <p>Griffiths Mental Development Scales (<a href="./references#CD015254-bbs2-0076" title="GriffithsR . The Griffiths Mental Development Scales from Birth to Two Years, Manual, the 1996 revision. Henley: Association for Research in Infant and Child Development, Test Agency, 1996.">Griffiths 1996</a>); </p> </li> <li> <p>McCarthy General Cognitive Index (<a href="./references#CD015254-bbs2-0092" title="McCarthyD . Manual for the McCarthy Scales of Children's Abilities. New York: Psychological Corp, 1972.">McCarthy 1972</a>); </p> </li> <li> <p>Bayley Scales of Infant and Toddler Development (<a href="./references#CD015254-bbs2-0065" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio, TX: Harcourt Assessment, Inc, 2006.">Bayley 2006</a>). </p> </li> </ul> </li> <li> <p>Psychosocial outcomes, measured using a validated scale, for example:</p> <ul id="CD015254-list-0013"> <li> <p>the Social Skills Scale of the Social Skills Rating System (<a href="./references#CD015254-bbs2-0075" title="GreshamFM , ElliottSN . Social Skills Rating System. Circle Pines, MN: American Guidance Service, 1990.">Gresham 1990</a>); </p> </li> <li> <p>Child Behavior Checklist (<a href="./references#CD015254-bbs2-0064" title="Achenbach TM . Child Behavior Checklist. In: KreutzerJS , DeLucaJ , CaplanB , editors(s). Encyclopedia of Clinical Neuropsychology. New York, NY: Springer, 2011.">Achenbach 2011</a>); </p> </li> <li> <p>Strengths and Difficulties Questionnaire (<a href="./references#CD015254-bbs2-0074" title="GoodmanR . The Strengths and Difficulties Questionnaire: a research note. Journal of Child Psychology and Psychiatry1997;38:581-6.">Goodman 1997</a>); </p> </li> <li> <p>Pediatric Symptom Checklist (<a href="./references#CD015254-bbs2-0081" title="JellinekMS , MurphyJM , RobinsonJ , FeinsA , LambS , FentonT . Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. Journal of Pediatrics1988;112(2):201-9. [DOI: 10.1016/s0022-3476(88)80056-8]">Jellinek 1988</a>). </p> </li> </ul> </li> <li> <p>Listening skills, for example listening to stories and instructions effectively. Given that there are few validated scales to assess listening skills in children with OME, we will include any methods used by trialists. </p> </li> <li> <p>Generic health‐related quality of life assessed using a validated instrument, for example: </p> <ul id="CD015254-list-0014"> <li> <p>EQ‐5D (<a href="./references#CD015254-bbs2-0100" title="RabinR , deCharroF . EQ-5D: a measure of health status from the EuroQol Group. Annals of Medicine2001;33(5):337-43.">Rabin 2001</a>); </p> </li> <li> <p>TNO AZL Children’s QoL (TACQOL) (<a href="./references#CD015254-bbs2-0113" title="VerripsGH , VogelsAGC , Verloove-VanhorickSP , FekkesM , KoopmanHM , KamphuisRP , et al. Health-related quality of life measure for children - the TACQOL. Journal of Applied Therapeutics1998;1(4):357-60.">Verrips 1998</a>); </p> </li> <li> <p>TNO AZL Pre‐school children QoL (TAPQOL) (<a href="./references#CD015254-bbs2-0071" title="FekkesM , TheunissenNC , BrugmanE , VeenS , VerripsEG , KoopmanHM , et al. Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1–5-year-old children. Quality of Life Research2000;9:961-72.">Fekkes 2000</a>); </p> </li> <li> <p>TNO AZL Infant Quality of Life (TAIQOL) (<a href="./references#CD015254-bbs2-0112" title="TNO—Prevention and Health/LUMC. TAIQOL—Questionnaire for parents of children aged 1—5 years. Leiden, The Netherlands: Leiden University Medical Center, 1997.">TNO 1997</a>); </p> </li> <li> <p>Infant Toddler Quality of Life Questionnaire (ITQOL) (<a href="./references#CD015254-bbs2-0083" title="LandgrafJM . The Infant/Toddler Child Health Questionnaire: conceptual framework, logic content, and preliminary psychometric results. Boston: Health Act, 1994.">Landgraf 1994</a>); </p> </li> <li> <p>Child Health Questionnaire (CHQ) (<a href="./references#CD015254-bbs2-0084" title="LandgrafJL , AbetzL , WareJE . The CHQ User’s Manual. Boston: The Health Institute, New England Medical Center, 1996.">Landgraf 1996</a>). </p> </li> </ul> </li> <li> <p>Parental stress, measured using a validated scale, for example:</p> <ul id="CD015254-list-0015"> <li> <p>Parenting Stress Index (<a href="./references#CD015254-bbs2-0063" title="AbidinRR . Parenting Stress Index: Professional Manual. Odessa, FL: Psychological Assessment Resources, 1995.">Abidin 1995</a>). </p> </li> </ul> </li> <li> <p>Vestibular function:</p> <ul id="CD015254-list-0016"> <li> <p>balance;</p> </li> <li> <p>co‐ordination.</p> </li> </ul> </li> <li> <p>Number of doctor‐diagnosed AOM episodes within a specified time frame.</p> </li> </ul> </p> <p>These outcomes were identified as the most important in two studies that aimed to develop a core outcome set for children with OME (<a href="./references#CD015254-bbs2-0066" title="BruceI , HarmanN , WilliamsonP , TierneyS , CalleryP , MohiuddinS , et al. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment2015;19(68):1-374. [DOI: 10.3310/hta19680]">Bruce 2015</a>; <a href="./references#CD015254-bbs2-0086" title="LiuPZ , Ismail-KochH , StephensonK , DonneAJ , FergieN , DerryJ , et al. A core outcome set for research on the management of otitis media with effusion in otherwise-healthy children. International Journal of Pediatric Otorhinolaryngology2020;134:110029. [DOI: 10.1016/j.ijporl.2020.110029]">Liu 2020</a>). As this review forms part of a suite of reviews of interventions for OME, not all outcomes are relevant for all reviews. </p> </section> </section> </section> <section id="CD015254-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. We contacted original authors for clarification and further data if trial reports were unclear, and we arranged translations of papers where necessary. The date of the search was 20 January 2023. </p> <section id="CD015254-sec-0026"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched:</p> <p> <ul id="CD015254-list-0017"> <li> <p>the Cochrane ENT Register (searched via the Cochrane Register of Studies to 20 January 2023); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL 2023, Issue 1), searched via the Cochrane Register of Studies to 20 January 2023; </p> </li> <li> <p>Ovid MEDLINE(R) Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 20 January 2023); </p> </li> <li> <p>Ovid EMBASE (1974 to 20 January 2023);</p> </li> <li> <p>Web of Science, Web of Science (1945 to 20 January 2023);</p> </li> <li> <p>ClinicalTrials.gov, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>: </p> <ul id="CD015254-list-0018"> <li> <p>searched via the Cochrane Register of Studies to 20 January 2023;</p> </li> <li> <p>searched via <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a> to 20 January 2023; </p> </li> </ul> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="https://apps.who.int/trialsearch/" target="_blank">https://apps.who.int/trialsearch/</a>: </p> <ul id="CD015254-list-0019"> <li> <p>searched via the Cochrane Register of Studies to 20 January 2023;</p> </li> <li> <p>searched via <a href="https://apps.who.int/trialsearch/" target="_blank">https://apps.who.int/trialsearch/</a> to 20 January 2023. </p> </li> </ul> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. The search strategies were designed to identify all relevant studies for a suite of reviews on various interventions for otitis media with effusion. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the Technical Supplement to Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> version 6.1) (<a href="./references#CD015254-bbs2-0085" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2020</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD015254-sec-0126">Appendix 1</a>. </p> </section> <section id="CD015254-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. The Information Specialist also ran non‐systematic searches of Google Scholar to retrieve grey literature and other sources of potential trials. </p> <p>We did not perform a separate search for adverse effects. We considered adverse effects described in included studies only. </p> </section> </section> <section id="CD015254-sec-0028"> <h3 class="title" id="CD015254-sec-0028">Data collection and analysis</h3> <section id="CD015254-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The Cochrane ENT Information Specialist used Cochrane's Screen4Me workflow to help assess the search results. Screen4Me comprises three components: </p> <p> <ol id="CD015254-list-0020"> <li> <p>Known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as 'a RCT' or as 'not a RCT'. </p> </li> <li> <p>The machine learning classifier (RCT model) (<a href="./references#CD015254-bbs2-0114" title="WallaceBC , Noel-StorrAH , MarshallIJ , CohenAM , SmalheiserNR , ThomasJ . Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. Journal of the American Medical Informatics Association2017;24(6):1165-8. [DOI: 10.1093/jamia/ocx053]">Wallace 2017</a>), available in the Cochrane Register of Studies (CRS‐Web), which assigns a probability of being a true RCT (from 0 to 100) to each citation. We assumed citations assigned a probability score below the cut‐point at a recall of 99% to be non‐RCTs. For those that scored on or above the cut‐point we either manually dual screened these results or sent them to Cochrane Crowd for screening. </p> </li> <li> <p>Cochrane Crowd is Cochrane's citizen science platform where the Crowd help to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, please go to the Screen4Me website on the Cochrane Information Specialist's <a href="https://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal" target="_blank">portal</a> and see <a href="./references#CD015254-bbs2-0091" title="MarshallJ , Noel-StorrAH , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):602-14.">Marshall 2018</a>; <a href="./references#CD015254-bbs2-0093" title="McDonaldS , Noel-StorrAH , ThomasJ . Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: Global Evidence Summit; 2017 Sep 13-17; Cape Town, South Africa. 2017.">McDonald 2017</a>; <a href="./references#CD015254-bbs2-0097" title="Noel-StorrAH . Cochrane Crowd: new ways of working together to produce health evidence. In: Evidence Live; 2018 Jun 18-20; Oxford, UK. 2018.">Noel‐Storr 2018</a>; <a href="./references#CD015254-bbs2-0111" title="ThomasJ , Noel-StorrAH , MarshallI , WallaceB , McDonaldS , MavergamesC , et al, Living Systematic Review Network. Living systematic reviews 2: combining human and machine effort. Journal of Clinical Epidemiology2017;91:31-7.">Thomas 2017</a>. </p> </li> </ol> </p> <p>Two review authors (KG, CM) independently screened titles and abstracts retrieved by the search to identify potentially relevant studies. At least two review authors (KG, CM, SM) then independently evaluated the full text of each potentially relevant study to determine whether it met the inclusion/exclusion criteria for this review. Any differences were resolved by discussion and consensus, with the involvement of a third author (KW) where necessary. </p> </section> <section id="CD015254-sec-0030"> <h4 class="title">Screening eligible studies for trustworthiness</h4> <p>Two review authors (KG, CM, MR, KW) appraised all studies meeting our inclusion criteria for trustworthiness using a screening tool developed by Cochrane Pregnancy and Childbirth. This tool includes specified criteria to identify studies that are considered sufficiently trustworthy to be included in the review (see <a href="./appendices#CD015254-sec-0127">Appendix 2</a> and <a href="#CD015254-fig-0001">Figure 1</a>). For any studies assessed as being potentially 'high risk', we attempted to contact the study authors to obtain further information or address any concerns. We had planned to exclude these studies from the review if we were unable to contact the authors, or there was persisting uncertainty about the study. However, when using the trustworthiness tool, there were only four studies where we had no concerns (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). </p> <div class="figure" id="CD015254-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015254-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> </div> <p>All the remaining studies had at least some concerns ‐ although this was often due to a paucity of information, rather than a specific concern over trustworthiness: </p> <p> <ul id="CD015254-list-0021"> <li> <p><a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a> and <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> all reported few (or no) baseline characteristics for the participants included in the study. We were therefore unable to assess whether there was excessive similarity between the randomised groups. </p> </li> <li> <p>Three studies recruited identical numbers of participants to each group, without a description of blocked randomisation (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>), and two studies did not clearly report the numbers allocated to each group (<a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). </p> </li> <li> <p>The number of participants lost to follow‐up was known (or appeared) to be zero for four trials, without adequate explanation (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>). </p> </li> <li> <p>Finally, we were unable to identify a prospective trial registration for one recently published study (<a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>). </p> </li> </ul> </p> <p>We were unsure whether this high level of studies with concerns reflected a genuine problem with the data from these studies, or whether the assessment tool was perhaps too sensitive. We note that this tool ‐ and others used for the same purpose ‐ has not yet been validated. </p> <p>Consequently, we decided to include all studies in the main analyses of this review, but we did investigate the effect of excluding studies with concerns over trustworthiness on the overall results (see <a href="#CD015254-sec-0042">Sensitivity analysis</a>). </p> </section> <section id="CD015254-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (KG, CM, MR, RV, KW) independently extracted outcome data from each study using a standardised data collection form. Where a study had more than one publication, we retrieved all publications to ensure complete extraction of data. Any discrepancies in the data extracted by the two authors were checked against the original reports, and differences were resolved through discussion and consensus, with recourse to a third author (KG or CM) where necessary. If required, we contacted the study authors for clarification. We included key characteristics of the studies, such as the study design, setting, sample size, population and the methods for defining or collecting outcome data in the studies. </p> <p>We extracted data on study findings according to treatment assignment, irrespective of whether study participants complied with treatment or received treatment to which they were randomised. </p> <p>In addition to extracting pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias, we extracted the following summary statistics for each study and outcome: </p> <p> <ul id="CD015254-list-0022"> <li> <p>For continuous data: the mean values, standard deviation and number of patients for each treatment group at the different time points for outcome measurement. Where endpoint data were not available, we extracted the values for change‐from‐baseline data instead. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. mean difference) from the studies. </p> </li> <li> <p>For binary data: we extracted information on the number of participants experiencing an event, and the number of participants assessed at that time point. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. risk ratio) from the studies. </p> </li> <li> <p>For ordinal scale data: we did not include any data from an ordinal scale in this review. </p> </li> </ul> </p> <p>We pre‐specified time points of interest for the outcomes in this review. Where studies reported data at multiple time points, we took the longest available follow‐up point within each of the specific time frames. For example, if a study reported an outcome at 4 months, 8 months and 12 months of follow‐up, then the 12‐month data are included for the time point &gt; 3 months to ≤ 1 year. </p> </section> <section id="CD015254-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (KG, CM, MR, RV, KW) undertook assessment of the risk of bias of the included studies independently, with the following taken into consideration, as guided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015254-bbs2-0078" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>): </p> <p> <ul id="CD015254-list-0023"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane risk of bias tool in RevMan 5.3 (<a href="./references#CD015254-bbs2-0101" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), which involves describing each of these domains as reported in the study and then assigning a judgement about the adequacy of each entry: 'low', 'high' or 'unclear' risk of bias. </p> </section> <section id="CD015254-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised dichotomous data ‐ such as presence of OME ‐ as risk ratios (RR) and 95% confidence intervals (CI), and we summarised continuous data as a mean difference (MD) and 95% CI. For the outcomes presented in the summary of findings tables, we also provide both the relative and absolute measures of effect. </p> </section> <section id="CD015254-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>For this review we anticipated that the unit of analysis would be the child. However, some studies reported findings by ear, and therefore we have used both the child and ear as the unit of analysis. </p> <p>All studies randomised participants to antibiotics or no treatment/placebo at the level of the child ‐ as this is an intervention that affects both ears. Some studies in this review included children with bilateral OME ‐ either exclusively (<a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>), or as a proportion of included participants (<a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>). This gave rise to a number of issues regarding the unit of analysis, as some studies reported outcomes (particularly the persistence of OME) for each ear. </p> <p>We considered that outcomes for ears within the same individual were likely to be correlated ‐ for example, if a child had resolution of OME in one ear, they may be more likely to experience resolution in the contralateral ear. Ears of the same individual are not independent. Standard meta‐analysis techniques assume that all data are independent. Therefore, inclusion of the raw data (for the number of ears) is likely to overestimate the precision of any effect, and result in an excessively narrow confidence interval. </p> <p>To account for this correlation, we used the suggested methods in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015254-bbs2-0078" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>), which are more commonly employed in the analysis of cluster‐randomised trials. We treated individuals who contributed two ears to the analysis (all of those with bilateral disease) as a 'cluster' of two data points. We then attempted to account for the correlation in these clusters, by assuming a certain correlation between ears of the same individual. We could not identify a figure for this correlation in the published literature, so we used an estimated correlation of 0.5 in the main analysis, but conducted sensitivity analyses using correlations of 0 and 1, to test the limits of this assumption. We then reduced the effective size of the trials by the 'design effect' ‐ which accounts for correlation between ears, and the average cluster size (which would be 2 for trials where all children had bilateral disease, and less than 2 if trials included a mixture of children with bilateral and unilateral disease). </p> <p>If we had identified cluster‐randomised trials, we would have assumed that the data from participants was no longer independent and adjusted our analyses accordingly, using the design effect approach as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015254-bbs2-0080" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>)<i>.</i> If we had identified cross‐over RCTs then we would have included data from the first phase of the trial only. However, this was not necessary for the review. We did identify one study with multiple arms (<a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>); in this instance, we pooled data from the three relevant arms for this review (all groups that received antibiotics) and compared them to the control group. </p> </section> <section id="CD015254-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors by email where data on an outcome of interest to the review were not reported, but the methods described in the paper suggested that the outcome was assessed. We did the same if not all data required for meta‐analysis were reported. If standard deviation data were not available, we approximated these using the standard estimation methods from P values, standard errors or 95% CIs (if these were reported), as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015254-bbs2-0080" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD015254-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the included studies for potential differences between them in the types of participants recruited, interventions or controls used, and the outcomes measured. We assessed statistical heterogeneity by considering both the I² statistic, which calculates the percentage of variability that is due to heterogeneity rather than chance (with values over 50% suggesting substantial heterogeneity), and the P value from the Chi² test (<a href="./references#CD015254-bbs2-0080" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD015254-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias as within‐study outcome reporting bias and between‐study publication bias. </p> <section id="CD015254-sec-0038"> <h5 class="title">Outcome reporting bias (within‐study reporting bias)</h5> <p>We assessed within‐study reporting bias by comparing the outcomes reported in the published report against the study protocol or trial registry, whenever this could be obtained. If the protocol or trial registry entry was not available, we compared the outcomes reported to those listed in the methods section. If results are mentioned but not reported adequately in a way that allows analysis (e.g. the report only mentions whether the results were statistically significant or not), bias in a meta‐analysis is likely to occur. We then sought further information from the study authors. If no further information could be found, we noted this as being a 'high' risk of bias when the risk of bias tool was used. If there was insufficient information to judge the risk of bias we noted this as an 'unclear' risk of bias (<a href="./references#CD015254-bbs2-0078" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> </section> <section id="CD015254-sec-0039"> <h5 class="title">Publication bias (between‐study reporting bias)</h5> <p>We planned to produce a funnel plot to explore possible publication biases, if we were able to pool 10 or more studies in a single analysis. However, this was not possible, as too few studies were included in the meta‐analyses. </p> </section> </section> <section id="CD015254-sec-0040"> <h4 class="title">Data synthesis</h4> <p>Where two or more studies reported the same outcome we performed a meta‐analysis using Review Manager 5 (<a href="./references#CD015254-bbs2-0101" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We report pooled effect measures for dichotomous outcomes as a risk ratio (RR) using the Mantel‐Haenszel methods. For continuous outcomes measured using the same scales we report the mean difference (MD). We used a random‐effects model. </p> <p>Where it was not possible to pool the findings from studies in a meta‐analysis, we have presented the results of each study and provide a narrative synthesis of findings. </p> </section> <section id="CD015254-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We proposed the following subgroup analyses if sufficient data were available in study reports: </p> <p> <ul id="CD015254-list-0024"> <li> <p>children with mild hearing loss versus moderate or worse;</p> </li> <li> <p>children with allergy versus those without (using the trialists' own definition);</p> </li> <li> <p>children aged up to four years versus children aged four years and over;</p> </li> <li> <p>children with previous ventilation tubes versus those without ventilation tubes;</p> </li> <li> <p>children with cleft palate versus children without;</p> </li> <li> <p>children with Down syndrome versus children without.</p> </li> </ul> </p> <p>However, we did not find any data suitable for conducting these subgroup analyses. No studies provided subgroup data for children with different features (for example, for those with mild hearing loss, compared to those with moderate or worse hearing loss). Many of the trials did not provide sufficient background information (for example on hearing level) for us to conduct subgroup analysis at the level of the individual study. Where data were provided, trials often recruited a mixed population that encompassed all subgroups (for example, most trials recruited children aged 1 to 12 years, not specifically children aged &lt; 4 years, or ≥ 4 years). </p> </section> <section id="CD015254-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>According to our protocol, we carried out sensitivity analyses to assess whether the results of a fixed‐effect model were notably different to those from a random‐effects model. </p> <p>We also planned to conduct a sensitivity analysis to exclude studies at high risk of bias (with four or more domains rated as high risk, using the risk of bias tool). This applied to a single study (<a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>). </p> <p>Where possible, we also carried out sensitivity analyses to assess the impact of excluding studies that had any concerns when using the Trustworthiness Screening tool. </p> <p>Two studies reported hearing data separately for right and left ears. We pooled these data for analysis, and made adjustments to account for the correlation between ears of the same individual. We were unable to identify a published correlation coefficient, therefore for the main analysis we assumed correlation of 0.5 between ears of the same individual, but tested this assumption using correlation coefficients of 0.3 and 0.7 in a sensitivity analysis. </p> </section> <section id="CD015254-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two independent authors (KG, CM) used the GRADE approach to rate the overall certainty of evidence using GRADEpro GDT (<a href="https://gradepro.org/" target="_blank">https://gradepro.org/</a>). The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct, and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD015254-list-0025"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision; and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>When assessing imprecision, we used a minimally important difference of a risk ratio (or odds ratio) of 0.8 or 1.25 for dichotomous outcomes. For most continuous data we considered a minimally important difference to be half of the standard deviation for the control/comparator group. The exception to this was hearing thresholds, where a difference of 10 dB HL was used as the minimally important difference. </p> <p>We included a summary of findings table, constructed according to the recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015254-bbs2-0080" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), for the following comparisons: </p> <p> <ul id="CD015254-list-0026"> <li> <p>oral antibiotics versus placebo;</p> </li> <li> <p>oral antibiotics versus no treatment.</p> </li> </ul> </p> <p>We prioritised the following four outcomes for the summary of findings tables:</p> <p> <ul id="CD015254-list-0027"> <li> <p>hearing;</p> </li> <li> <p>disease‐specific quality of life;</p> </li> <li> <p>presence/persistence of OME;</p> </li> <li> <p>adverse events ‐ anaphylactic reaction.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015254-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015254-sec-0044"></div> <section id="CD015254-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD015254-sec-0046"> <h4 class="title">Results of the search</h4> <p>The searches (September 2021 and January 2023) retrieved a total of 7441 records. This reduced to 4157 after the removal of duplicates. The Cochrane ENT Information Specialist sent all 4157 records to the Screen4Me workflow. The Screen4Me workflow identified 84 records as having previously been assessed: 50 had been rejected as not RCTs and 34 had been assessed as possible RCTs. The remaining 4073 references were sent to the RCT classifier, which rejected an additional 1514 records as not RCTs (with 99% sensitivity) and 116 records as possible RCTs. The Cochrane Crowd assessed 2443 of the remaining references, rejecting 1313 as not RCTs and identifying 1130 as possible RCTs. Following this process, the Screen4Me workflow rejected a total of 2877 records and identified 1280 possible RCTs for title and abstract screening (see <a href="#CD015254-tbl-0003">Table 1</a>). </p> <div class="table" id="CD015254-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Possible RCTs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rejected</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Known assessments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT classifier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1514</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cochrane Crowd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2877</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT: randomised controlled trial</p> </div> </div> <p>We excluded 76 additional duplicates. We screened the titles and abstracts of the remaining 1204 records. We discarded 886 records and retrieved 318 full‐text records. We subsequently discarded an additional 239 irrelevant records and removed an additional five duplicates. </p> <p>We excluded 49 records (linked to 41 studies) with reasons recorded in the review (see <a href="#CD015254-sec-0062">Excluded studies</a>). </p> <p>We included 19 studies (23 records) where results were available (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). </p> <p>We identified two studies that are awaiting assessment because we did not have enough information to determine eligibility (<a href="./references#CD015254-bbs2-0061" title="KoayB , ComminsDJ , BatesS , MitchellB , MooreA , BatesG , et al. In search of a medical treatment for otitis media with effusion (OME): a randomised double-blind controlled trial (RCT). In: 7th International Congress of Pediatric Otorhinolaryngology. Helsinki, Finland, 7-10 June, 1998. 1998:64. [ABSTRACT NUMBER: 289] [CENTRAL: CN-00292550] ">Koay 1998</a>; <a href="./references#CD015254-bbs2-0062" title="TawfikS , BelalA , SorourW . A comparative study of the different treatment modalities of otitis media with effusion in children. In: 8th International Congress of Paediatric Otorhinolaryngology (ESPO). Oxford, UK, 11-14 September, 2002. 2002:151, Abstract No. P2.26. [CENTRAL: CN-00508402] ">Tawfik 2002</a>). See <a href="./references#CD015254-sec-0138" title="">Characteristics of studies awaiting classification</a>. We did not identify any ongoing studies. </p> <p>A flow chart of study retrieval and selection is provided in <a href="#CD015254-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD015254-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="A flow chart of study retrieval and selection." data-id="CD015254-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>A flow chart of study retrieval and selection.</p> </div> </div> </div> </section> <section id="CD015254-sec-0047"> <h4 class="title">Included studies</h4> <p>A full description of each included study is given in <a href="./references#CD015254-sec-0136" title="">Characteristics of included studies</a>, and a summary of the main features of all studies is shown in <a href="#CD015254-tbl-0004">Table 2</a>. </p> <div class="table" id="CD015254-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison of studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up (main outcomes reported at this time)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with chronic OME (≥ 3 months), without response to 3 courses of antibiotics (n = 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐amoxiclav, 40 mg/kg/day in 3 divided doses for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A third arm received anti‐reflux medication, but this was not relevant to this review, therefore data were not extracted </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with at least 3 months duration of uni‐ or bilateral OME (n = 264) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study conducted in Denmark. No details on participant recruitment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks treatment with amoxicillin and clavulanate potassium. Concentration not stated. Children aged 1 to 5 had 5 mL 3 times daily, children aged 6 to 10 had 7.5 mL 3 times daily. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this study did not provide any data for outcomes of interest in this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 14 years with OME for less than 3 months (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre, university ENT department in China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 15 mg/kg/day in 2 divided doses for 1 week, then 5 to 8 mg/kg/day until the tympanogram was type A (range of treatment 5 to 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical glucocorticoid spray was given to all participants for 12 weeks</p> <p>It appears that all participants underwent tympanocentesis at the start of the trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two children in the intervention group actually received azithromycin, instead of clarithromycin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with bilateral OME, aged less than 2 years (n = 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxazole‐trimethoprim 20 mg/kg/day in a single night‐time dose for 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated to be placebo, but no information on the nature of the placebo is provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this trial also included older children, but they received a different intervention, not relevant for this review </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &lt; 12 years with uni‐ or bilateral OME for at least 3 months (n = 91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cefaclor 20 mg/kg twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 5 years with OME for ≤ 6 weeks (n = 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre, university hospital study from USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trimethoprim‐sulfamethoxazole (8 mg and 40 mg/kg/day respectively) in 2 divided doses for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with uni‐ or bilateral OME for at least 3 months (n = 81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cefixime 8 mg/kg per day in 2 divided doses for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suspension of similar appearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that a third arm received antibiotics and steroids. Data are not relevant for this review, so have not been included here. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with uni‐ or bilateral OME (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ampicillin/sulbactam 25 mg/kg/day, in 2 divided doses for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that a third arm received antibiotics and steroids. Data are not relevant for this review, so have not been included here. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aboriginal infants aged &lt; 12 months with OME (n = 103)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruited from 3 Aboriginal communities in Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 24 weeks, or until bilateral normal middle ear status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suspension of equivalent volume</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 12 years with OME (n = 340)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 40 mg/kg per day in 3 divided doses for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups also received an additional placebo for the third arm of this study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A third treatment arm received antibiotics and antihistamine. Data were not relevant for this review, therefore not included. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 12 years with OME (n = 331)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin and sulfisoxazole (50 mg and 150 mg/kg/day respectively) in 4 divided doses for 2 weeks </p> <p>or</p> <p>Cefaclor 40 mg/kg/day in 3 divided doses for 2 weeks</p> <p>or</p> <p>Amoxicillin 40 mg/kg/day in 3 divided doses for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that data from all of the arms receiving antibiotics have been pooled for the purposes of analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 8 months to 13 years with unilateral or bilateral OME for at least 3 months (52 ears assessed, number of children unclear) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in both groups received a daily dose of a decongestant syrup (chlorhydrate ambroxol, dose dependent on age) for the duration of the trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 7 years with OME for at least 3 months (n = 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre study from Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceftibuten 9 mg/kg/day in 1 daily dose for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (nasal saline drops)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 15 years with bilateral OME for at least 3 months, awaiting ventilation tube insertion (n = 147) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin 50 mg/kg/day in 2 divided doses for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 8 years with OME for ≥ 2 months, who had received no previous treatment (n = 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactose powder placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received an additional placebo to account for the third intervention in this study (antibiotics plus prednisone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that there was a third arm in this study, where participants received both antibiotics and steroids. Data have not been extracted for this review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 11 years with OME (n = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg trimethoprim and 18.5 mg sulfadiazine/kg/day in 2 divided doses for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received an additional placebo to account for the third intervention in this study (antibiotics plus prednisone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that there was a third arm in this study, where participants received both antibiotics and steroids. Data have not been extracted for this review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1.5 to 11 years with unilateral or bilateral OME for at least 3 months (n = 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin ethylsuccinate 20 to 30 mg/kg twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this study did not provide any data for outcomes of interest in this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with at least 3 months of unilateral or bilateral OME (n = 264) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin and clavulanate potassium with 125 mg/31.25 mg 3 times daily (if aged 1 to 5) or 187 mg/46.9 mg 3 times daily (if aged 6 to 10) for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In patients with bilateral disease, a ventilation tube was inserted in the right ear, and the left ear was included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged ≤ 6 years with at least 3 months of OME (n = 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 20 mg/kg/day plus 5 mg/kg/day clavulanic acid in 3 divided doses for 14 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One drop of decongestant (oxymetazoline 0.25%) 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OME: otitis media with effusion</p> </div> </div> <section id="CD015254-sec-0048"> <h5 class="title">Study design</h5> <p>All the included studies were described as randomised controlled trials.</p> </section> <section id="CD015254-sec-0049"> <h5 class="title">Participants</h5> <p>Most of the studies recruited children aged from approximately 2 to 12 years, with bilateral or unilateral OME. One study included participants of mixed ages, but we were only able to use the data for children aged &lt; 2 years (as older children received a different intervention; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>). </p> <p>Many, but not all, studies required participants to have a diagnosis of OME that had persisted for at least three months (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). One study required the persistence of OME for at least six weeks (<a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>), and another for two months (<a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). A single study specifically recruited individuals with short duration of symptoms (&lt; 3 months; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>), whilst the remainder did not specify the duration of OME. </p> <p>Few studies provided information on the extent of hearing impairment at baseline.</p> </section> <section id="CD015254-sec-0050"> <h5 class="title">Interventions and comparisons</h5> <section id="CD015254-sec-0051"> <h6 class="title">Comparison 1: Oral antibiotics versus placebo</h6> <p>We identified 11 studies for this comparison (<a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). However, <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a> does not provide data for any outcomes of interest to this review. </p> <p>A number of different antibiotics were used, including:</p> <p> <ul id="CD015254-list-0028"> <li> <p>Penicillins</p> <ul id="CD015254-list-0029"> <li> <p>Amoxicillin (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). </p> </li> <li> <p>Co‐amoxiclav (<a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). </p> </li> </ul> </li> <li> <p>2nd or 3rd generation cephalosporins</p> <ul id="CD015254-list-0030"> <li> <p>Cefaclor (<a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>). </p> </li> <li> <p>Cefixime (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>). </p> </li> <li> <p>Ceftibuten (<a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>). </p> </li> </ul> </li> <li> <p>Macrolides</p> <ul id="CD015254-list-0031"> <li> <p>Erythromycin (<a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>). </p> </li> <li> <p>Erythromycin and sulfisoxazole (<a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>). </p> </li> </ul> </li> <li> <p>Trimethoprim and sulfamethoxazole (<a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>), or trimethoprim and sulfadiazine (<a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>). </p> </li> </ul> </p> <p>Most studies provided antibiotic treatment for 10 to 14 days, although some required a longer course (28 to 30 days: <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>) and one used treatment for 24 weeks (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>). Three studies assessed outcomes as soon as the antibiotics were stopped (<a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). Four studies assessed outcomes approximately two weeks after stopping antibiotics (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>), and the remaining four studies had a delay of approximately six to eight weeks before assessing outcomes (<a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>). </p> </section> <section id="CD015254-sec-0052"> <h6 class="title">Comparison 2: Oral antibiotics versus no treatment</h6> <p>We identified eight studies for this comparison (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>). However, <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a> does not provide data for any outcomes of interest to this review. </p> <p>A number of different antibiotics were used, including:</p> <p> <ul id="CD015254-list-0032"> <li> <p>Penicillins</p> <ul id="CD015254-list-0033"> <li> <p>Amoxicillin (<a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>). </p> </li> <li> <p>Co‐amoxiclav (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>). </p> </li> <li> <p>Ampicillin and sulbactam (<a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>). </p> </li> </ul> </li> <li> <p>2nd or 3rd generation cephalosporins</p> <ul id="CD015254-list-0034"> <li> <p>Cefaclor (<a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>). </p> </li> </ul> </li> <li> <p>Macrolides</p> <ul id="CD015254-list-0035"> <li> <p>Erythromycin (<a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>). </p> </li> <li> <p>Clarithromycin (<a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>). </p> </li> </ul> </li> <li> <p>Trimethoprim and sulfamethoxazole (<a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>). </p> </li> </ul> </p> <p>The duration of treatment varied from a minimum of 8 or 10 days (<a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>) to a maximum of three months (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>). Follow‐up was typically at the end of the treatment (immediately after antibiotics were discontinued), except for <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> (5 to 12 weeks of treatment, follow‐up at 12 weeks) and <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a> (eight days of treatment, follow‐up at three months). </p> </section> </section> <section id="CD015254-sec-0053"> <h5 class="title">Outcomes</h5> <section id="CD015254-sec-0054"> <h6 class="title">Hearing</h6> <section id="CD015254-sec-0055"> <p><b>Return to normal hearing</b></p> <p>As with other reviews in this suite, few studies reported our preferred outcome measure for hearing ‐ the proportion of children in whom hearing returns to normal. This outcome was only measured by two studies. <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> reported the proportion of children in whom there was complete resolution of the air‐bone gap in the worst affected ear, after two months of follow‐up. <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a> reported the proportion of children in whom "hearing thresholds returned to normal", but did not provide a definition of normal hearing. </p> </section> <section id="CD015254-sec-0056"> <p><b>Final hearing thresholds or change in hearing threshold</b></p> <p>Two studies assessed speech reception thresholds (<a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>); one of these also assessed speech awareness thresholds for younger children (<a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>). One study reported the mean air‐bone gap after three months of follow‐up (<a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>). </p> </section> </section> <section id="CD015254-sec-0057"> <h6 class="title">Disease‐specific quality of life</h6> <p>We did not identify any studies that assessed disease‐specific quality of life.</p> </section> <section id="CD015254-sec-0058"> <h6 class="title">Adverse events: anaphylaxis</h6> <p>None of the studies included in this review specifically reported on the occurrence of anaphylaxis. However, five studies did provide some information, which suggested that no anaphylactic reactions had occurred (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>). </p> </section> <section id="CD015254-sec-0059"> <h6 class="title">Presence/persistence of OME</h6> <p>We noted that there was some variation in how the outcome 'presence or persistence of OME' was assessed and reported. Most studies reported on clearance or resolution of OME, i.e. the number of participants with no evidence of OME in either ear at follow‐up. Many studies included participants with both bilateral and unilateral diseases. Consequently, for those with bilateral disease, this would only include children in whom both ears had resolved. </p> <p>For the majority of studies we were therefore able to identify the proportion of participants in each in whom <i>at least one ear</i> had persistent OME at the follow‐up time ‐ both ears were assessed in every participant. However, some studies reported this outcome slightly differently: </p> <p> <ul id="CD015254-list-0036"> <li> <p>Two studies only assessed the ear(s) that had been affected at the start of the trial (<a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>). Both ears were assessed for those with bilateral disease, but for those with unilateral disease only one ear was checked at follow‐up ‐ the ear affected by OME at the start of the study. </p> </li> <li> <p>One study only classed OME as persistent if any ear affected at baseline was still affected at follow‐up (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>). For those with bilateral disease, if one ear had resolved at follow‐up then the child was not considered to have "persistent OME". </p> </li> <li> <p>One study assessed only one ear in each participant: for those with bilateral disease, the "worst affected ear" was assessed at follow‐up (<a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). </p> </li> <li> <p>Some studies assessed and reported the outcome (presence of OME) at the level of the individual ear, rather than at the level of the participant. Children with bilateral disease therefore contributed two data points to the outcome measure. We are aware that the outcomes for ears within the same individual are likely to be strongly correlated, and these data are clustered. We therefore adjusted these data according to the methods in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, using an estimated intra‐cluster correlation coefficient of 0.5. However, we also conducted a sensitivity analysis to assess the impact of this adjustment, using an ICC of zero (no correlation between the ears of a given individual) and one (complete correlation between the ears of a given individual). </p> </li> </ul> </p> <p>The underlying approach in all the studies was to assess the difference in persistence of OME, albeit with slightly different methods of measuring this effect. We therefore considered that it was reasonable to pool the data in a meta‐analysis. However, we also undertook a subgroup analysis to identify whether there may be differences in the effect estimates depending on which method of outcome assessment was used. </p> </section> <section id="CD015254-sec-0060"> <h6 class="title">Adverse events</h6> <p>Adverse events were inconsistently reported across the studies. Data were frequently presented for only one group ‐ those who received the intervention. It was not clear whether this was because no events occurred in the placebo arm, or whether adverse events were not assessed in this group. </p> </section> <section id="CD015254-sec-0061"> <h6 class="title">Number of doctor‐diagnosed episodes of acute otitis media</h6> <p>This outcome was only assessed by three studies (<a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>), and was reported as the proportion of participants who experienced at least one episode of acute otitis media during a four‐week follow‐up period. </p> <p>We did not identify any data for our other secondary outcomes of interest (<a href="#CD015254-sec-0024">Secondary outcomes</a>), including expressive and receptive language skills, cognitive development, psychosocial skills, listening skills, generic health‐related quality of life, parental stress and vestibular function. </p> </section> </section> </section> <section id="CD015254-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 41 studies (linked to 49 records) from this review. The main reason for exclusion of each study is listed below: </p> <p> <ul id="CD015254-list-0037"> <li> <p>Nineteen articles were not randomised controlled trials (<a href="./references#CD015254-bbs2-0025" title="deCastroFJ , JaegerRW , MartinL , TemeckJW , TournourB . Serous otitis media. A double-blind trial with sulfisoxazole. Missouri Medicine1982;79(9):629-30. [CENTRAL: CN-00029746] [EMBASE: 13245698] [PMID: 6757712]">de Castro 1982</a>; <a href="./references#CD015254-bbs2-0027" title="EidenP . Antibiotic therapy for otitis media infection with effusion in children can make surgery unnecessary. Deutsche Apotheker Zeitung1997;137(8):41-2. ">Eiden 1997</a>; <a href="./references#CD015254-bbs2-0029" title="FujitaA , KurataK , TakahashiH , TakagitaS . Clinical efficacy of clarithromycin treatment of refractory otitis media with effusion. Practica Otologica1994;87(9):1287-91. ">Fujita 1994</a>; <a href="./references#CD015254-bbs2-0031" title="GasperK , St AnnaL , MontgomeryL . Are antibiotics effective for otitis media with effusion?Journal of Family Practice2003;52(4):321-3. [EMBASE: 36427691]">Gasper 2003</a>; <a href="./references#CD015254-bbs2-0032" title="GibsonPG , StuartJE , WlodarczykJ , OlsonLG , HensleyMJ . Nasal inflammation and chronic ear disease in Australian Aboriginal children. Journal of Paediatrics and Child Health1996;32(2):143-7. [CENTRAL: CN-00131589] [PMID: 8860389]">Gibson 1996</a>; <a href="./references#CD015254-bbs2-0034" title="HozawaT . Evidence-based macrolide therapy for children with serous otitis media. Japanese Journal of Antibiotics2001;54(Suppl C):30-2. [EMBASE: 36495134]">Hozawa 2001</a>; <a href="./references#CD015254-bbs2-0035" title="IinoY , IshitoyaJ , IkedaM , ItoY , UsamiM , KawashiroN , et al. Factors on delayed recovery of otitis media with effusion in children--clinical and bacteriological study. Nihon Jibiinkoka Gakkai Kaiho1989;92(8):1183-91. [CENTRAL: CN-00063873] [PMID: 2685215]">Iino 1989</a>; <a href="./references#CD015254-bbs2-0036" title="IinoY . Efficacy of macrolide therapy for children with serous otitis media. Japanese Journal of Antibiotics2001;54 Suppl C:23-5. [EMBASE: 36495133] [PMID: 12575412]">Iino 2001</a>; <a href="./references#CD015254-bbs2-0037" title="KobayashiK . Applicability of long-term low-dosage macrolide therapy for children with serous otitis media. Japanese Journal of Antibiotics2001;54 Suppl C:26-9. [PMID: 12627599]">Kobayashi 2001</a>; <a href="./references#CD015254-bbs2-0038" title="KuriyamaK . Synergistic effect of antibiotics and Chinese drug on recurrent otitis media. Otolaryngology1980;52(9):617-22. [EMBASE: 11228874]">Kuriyama 1980</a>; <a href="./references#CD015254-bbs2-0039" title="LeonettiJP , StankiewiczJA . Antimicrobial prophylaxis for recurrent otitis media. Otolaryngology - Head &amp; Neck Surgery1988;99(1):81-2. [PMID: 3140190]">Leonetti 1988</a>; <a href="./references#CD015254-bbs2-0041" title="ParadiseJ , CampbellT , DollaghanC , FeldmanH , BernardB , ColbornK , et al. Receptive vocabulary, cognition, and parent-rated behavior at age 3 years in relation to otitis media in the first 3 years of life. In: Abstract Book of the Association of Health Service Research. Vol. 14. 1997:350-1. [CENTRAL: CN-00452820] ">Paradise 1997</a>; <a href="./references#CD015254-bbs2-0042" title="ParleaE , GeorgescuM , CalarasuR . Tympanometry as a predictor factor in the evolution of otitis media with effusion. Journal of Medicine and Life2012;5(4):452-4. [CENTRAL: CN-00850240] [EMBASE: 369159817] [PMID: 23346249]">Parlea 2012</a>; <a href="./references#CD015254-bbs2-0044" title="PersicoM , PodoshinL , FradisM , FradisM . Otitis media with effusion: a steroid and antibiotic therapeutic trial before surgery. Annals of Otology, Rhinology, and Laryngology1978;87:191-5. [CENTRAL: CN-00449363] [PMID: 646286]">Persico 1978</a>; <a href="./references#CD015254-bbs2-0051" title="ShubichI . Otitis media with effusion and allergy control in children: a prospective study. In: Sixth International Symposium on Otitis Media; 1996; Fort Lauderdale (FL). 1996:173-4. [CENTRAL: CN-00452904] ">Shubich 1996</a>; <a href="./references#CD015254-bbs2-0052" title="SmalesO . Antibiotics for otitis media with effusion. New Zealand Medical Journal1992;105(927):42. [PMID: 1538867]">Smales 1992</a>; <a href="./references#CD015254-bbs2-0053" title="StenstromR , PlessIB , BernardP . Hearing thresholds and tympanic membrane sequelae in children managed medically or surgically for otitis media with effusion. Archives of Pediatrics &amp; Adolescent Medicine2005;159(12):1151-6. [CENTRAL: CN-00532329] [PMID: 16330739]">Stenstrom 2005</a>; <a href="./references#CD015254-bbs2-0055" title="vanBalenFA . Antibiotics in otitis media with effusion [Antibiotica bij otitis media met effusie]. Nederlands Tijdschrift voor Geneeskunde1997;141(8):401-2. [PMID: 9157309]">van Balen 1997</a>; <a href="./references#CD015254-bbs2-0060" title="ZocconiE . Antibiotics and oral steroids in the treatment of otitis media with effusion. Pediatria Medica e Chirurgica1994;16(3):273-5. ">Zocconi 1994</a>). </p> </li> <li> <p>Twelve articles considered an incorrect population, enroling participants who did not have OME, including: </p> <ul id="CD015254-list-0038"> <li> <p>children with acute otitis media (<a href="./references#CD015254-bbs2-0043" title="PerrinJM , CharneyE , MacWhinneyJBJ , McInernyTK , MillerRL , NazarianLF . Sulfisoxazole as chemoprophylaxis for recurrent otitis media. A double-blind crossover study in pediatric practice. New England Journal of Medicine1974;291(13):664-7. [CENTRAL: CN-00010786] [PMID: 4153093]">Perrin 1974</a>); </p> </li> <li> <p>children with a persistent effusion after a recent episode of acute otitis media (<a href="./references#CD015254-bbs2-0023" title="CorwinMJ , WeinerLB , DanielsD . Efficacy of oral antibiotics for the treatment of persistent otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1986;11(2):109-12. [CENTRAL: CN-00044237] [PMID: 3488978]CorwinMJ , WeinerLB , DanielsDA , DanielsDA . Effects of oral antibiotics on the outcome of serous otitis media. Pediatric Research1982;16:238A. [CENTRAL: CN-00449256] ">Corwin 1986</a>; <a href="./references#CD015254-bbs2-0033" title="GiebinkGC , BataldenPB , LeCT , RussJN , KnoxJK , AndersonRS . Randomized controlled trial comparing trimethoprim-sulfamethoxazole, prednisone, ibuprofen, and no treatment in chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , editors(s). Recent Advances Otitis Media: Proceedings of the Fourth International Symposium; 1988 Jun 1-4 Toronto (Canada). 1988:240-4. [CENTRAL: CN-00452593] GiebinkGS , BataldenPB , LeCT , LassmanFM , BuranDJ , SeltzAE . A controlled trial comparing three treatments for chronic otitis media with effusion. Pediatric Infectious Disease Journal1990;9(1):33-40. [CENTRAL: CN-00065358] [PMID: 2405348]">Giebink 1990</a>; <a href="./references#CD015254-bbs2-0048" title="SchlossMD , DempseyEE , RishikofE , SorgaS , GraceMGA . Double blind study comparing erythromycin-sulfisoxazole (Pediazole) TID to placebo in chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , editors(s). Recent Advances on Otitis Media: Proceedings of the 4th International Symposium; 1987 Jun 1-4; Toronto (ON). 1988:261-3. [CENTRAL: CN-00452893] SchlossMD , RishikofE , SorgerS , DempseyEE , GraceM . A double-blind study comparing erythromycin-sulfisoxazole (Pediazole (R)) t.i.d. with placebo in chronic otitis media with effusion. Today's Therapeutic Trends1988;5(4):43-56. [CENTRAL: CN-00192403] [EMBASE: 1988100915]">Schloss 1988</a>); </p> </li> <li> <p>children with recurrent episodes of acute otitis media (<a href="./references#CD015254-bbs2-0028" title="FerraraS , SammartanoD , FerraraP . Long-term management of recurrent otitis media with effusion in children. In: XVIII IFOS World Congress; 2005 Jun 25-30; Rome (Italy). 2005. [CENTRAL: CN-00526409] ">Ferrara 2005</a>; <a href="./references#CD015254-bbs2-0030" title="GaskinsJD , HoltRJ , KyongCU , WeartCW , WardJ . Chemoprophylaxis of recurrent otitis media using trimethoprim/sulfamethoxazole. Drug Intelligence &amp; Clinical Pharmacy1982;16(5):387-90. [CENTRAL: CN-00028043] [PMID: 7084029]">Gaskins 1982</a>; <a href="./references#CD015254-bbs2-0045" title="PrincipiN , MarchisioP , MassironiE , GrassoRM , FilibertiG . Prophylaxis of recurrent acute otitis media and middle-ear effusion. Comparison of amoxicillin with sulfamethoxazole and trimethoprim. American Journal of Diseases of Children1989;143(12):1414-8. [CENTRAL: CN-00063984] [PMID: 2589274]">Principi 1989</a>; <a href="./references#CD015254-bbs2-0046" title="RoarkR , BermanS . Continuous twice daily or once daily amoxicillin prophylaxis compared with placebo for children with recurrent acute otitis media. Pediatric Infectious Disease Journal1997;16(4):376-81. [CENTRAL: CN-00138754] [PMID: 9109139]">Roark 1997</a>; <a href="./references#CD015254-bbs2-0049" title="SchwartzRH , RodriguezWJ . Trimethoprim-sulfamethoxazole treatment of persistent otitis media with effusion. Pediatric Infectious Disease Journal1982;1(5):333-5. [CENTRAL: CN-00030082] [PMID: 7155965]">Schwartz 1982</a>; <a href="./references#CD015254-bbs2-0050" title="SchwartzRH , PugliseJ , RodriguezWJ . Sulphamethoxazole prophylaxis in the otitis-prone child. Archives of Disease in Childhood1982;57(8):590-3. [CENTRAL: CN-00028780] [PMID: 7051984]">Schwartz 1982a</a>; <a href="./references#CD015254-bbs2-0054" title="TracyJM , DemainJG , HoffmanK , GoetzDW . Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Annals of Allergy, Asthma &amp; Immunology1995;74:59. [CENTRAL: CN-00285148] TracyJM , DemainJG , HoffmanKM , GoetzDW . Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Annals of Allergy, Asthma &amp; Immunology1998;80(2):198-206. [CENTRAL: CN-00148310] [PMID: 9494455]">Tracy 1995</a>; <a href="./references#CD015254-bbs2-0056" title="VarsanoI , VolovitzB , MimouniF . Sulfisoxazole prophylaxis of middle ear effusion and recurrent acute otitis media. American Journal of Diseases of Children1985;139(6):632-5. [CENTRAL: CN-00038335] [PMID: 3890523]">Varsano 1985</a>). </p> </li> </ul> </li> <li> <p>Six articles used an intervention other than antibiotics (<a href="./references#CD015254-bbs2-0020" title="BermanS , GroseK , NussR , Huber-NavinC , RoarkR , GabbardSA , et al. Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatric Infectious Disease Journal1990;9(8):533-8. [CENTRAL: CN-00071176] [PMID: 2235167]">Berman 1990</a>; <a href="./references#CD015254-bbs2-0021" title="BernardPA , StenstromRJ , FeldmanW , Durieux-SmithA . Randomized, controlled trial comparing long-term sulfonamide therapy to ventilation tubes for otitis media with effusion. Pediatrics1991;88(2):215-22. [CENTRAL: CN-00077175] [PMID: 1861917]FeldmanW , BernardP , SmithA , StenstromR . Sulfonamide prophylaxis vs ventilation tubes in hearing-loss due to recurrent otitis-media with effusion (Rome) - preliminary results of a randomized controlled trial. Clinical and Investigative Medicine [Medecine Clinique et Experimentale]1987;4:A33. [CENTRAL: CN-02494379] FeldmanW , BernardP , SmithA , StenstromR . Sulfonamide prophylaxis vs ventilation tubes in hearing-loss due to recurrent otitis-media with effusion - preliminary results of a randomized controlled trial. American Journal of Diseases of Children1987;4:389-9. [CENTRAL: CN-02494378] FeldmanW , BernardP , SmithA , StenstromR . Ventilation tubes vs sulfonamide prophylaxis for recurrent acute otitis-media or serious otitis-media - follow-up on a randomized, controlled trial. American Journal of Diseases of Children1988;4(4):407-7. [CENTRAL: CN-02494377] ">Bernard 1991</a>; <a href="./references#CD015254-bbs2-0022" title="ChoungYH , ShinYR , ChoiSJ , ParkK , ParkHY , LeeJB , et al. Management for the children with otitis media with effusion in the tertiary hospital. Clinical and Experimental Otorhinolaryngology2008;1(4):201-5. [CENTRAL: CN-00671567] ">Choung 2008</a>; <a href="./references#CD015254-bbs2-0024" title="DalyK , GiebinkGS , BataldenPB , AndersonRS , LeCT , LindgrenB , et al. Resolution of otitis media with effusion with the use of a stepped treatment regimen of trimethoprim-sulfamethoxazole and prednisone. Pediatric Infectious Disease Journal1991;10(7):500-6. [CENTRAL: CN-00077629] [PMID: 1876465]DalyK , GiebinkGS , LindgrenB , AndersonRS . Controlled clinical trial for prevention of chronic otitis media with effusion. In: LimDJ , BluestoneCD , KleinJO , editors(s). Recent Advances on Otitis Media: Proceedings of the 4th International Symposium; 1987 Jun 1-4; Toronto (ON). 1987:247-50. [CENTRAL: CN-00452502] ">Daly 1991</a>; <a href="./references#CD015254-bbs2-0047" title="RohailA , GillZI , ButtMR . A comparison of medical treatment versus surgical treatment for the management of otitis media with effusion. Annals of King Edward Medical College2006;12(1):64-7. [CENTRAL: CN-00597368] ">Rohail 2006</a>; <a href="./references#CD015254-bbs2-0057" title="VelepicM , StarcevicR , BonifacicM , TicacR , KujundzicM , UdovicDS , et al. The clinical status of the eardrum: an inclusion criterion for the treatment of chronic secretory otitis media in children. International Journal of Pediatric Otorhinolaryngology2011;75(5):686-90. [CENTRAL: CN-00784332] [EMBASE: 51315541] [PMID: 21397957]">Velepic 2011</a>). </p> </li> <li> <p>Three studies compared the use of antibiotics to a different, active intervention (not to placebo or no treatment), including: </p> <ul id="CD015254-list-0039"> <li> <p>different doses of the same antibiotic (<a href="./references#CD015254-bbs2-0026" title="DonaldsonJD , MartinGF , MaltbyCC , SeywerdEB . The efficacy of pulse-dosed antibiotic therapy in the management of persistent otitis media with effusion. Journal of Otolaryngology1990;19(3):175-8. [CENTRAL: CN-00068309] [PMID: 2192073]">Donaldson 1990</a>); </p> </li> <li> <p>a decongestant (<a href="./references#CD015254-bbs2-0040" title="MarksNJ , MillsRP , ShaheenOH . A controlled trial of cotrimoxazole therapy in serous otitis media. Journal of Laryngology and Otology1981;95(10):1003-9. [CENTRAL: CN-00026372] [EMBASE: 1982075258] [PMID: 7028896]">Marks 1981</a>); </p> </li> <li> <p>a different antibiotic (<a href="./references#CD015254-bbs2-0059" title="YinTF , TangQL , XieDH , LuYD . Efficacy of cefaclor in treating children with secretory otitis media. Shanghai Medicine2002;23(2):65-6. [CENTRAL: CN-00416980] ">Yin 2002</a>). </p> </li> </ul> </li> </ul> </p> <p><a href="./references#CD015254-bbs2-0058" title="YeldandiV , MacLeodC , MulvaneyAM . Open-label, randomised, comparative study of usual care with or without clarithromycin suspension in serous otitis media with inflammation. In: 22nd International Congress of Chemotherapy; 2001 Jun 30-Jul 3; Amsterdam (the Netherlands). 2001. [ABSTRACT NO.: P10.009] [CENTRAL: CN-00453008] ">Yeldandi 2001</a> did use a relevant comparator. However, both groups received co‐interventions, and the nature and frequency of these was not balanced across the groups. This rendered the comparison inaccurate, therefore we excluded this study. </p> </section> </section> <section id="CD015254-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD015254-fig-0003">Figure 3</a> for a summary of the risk of bias across all included studies, and <a href="#CD015254-fig-0004">Figure 4</a> for details of the risk of bias for individual studies. </p> <div class="figure" id="CD015254-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies)." data-id="CD015254-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies). </p> </div> </div> </div> <div class="figure" id="CD015254-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary (our judgements about each risk of bias item for each included study)." data-id="CD015254-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary (our judgements about each risk of bias item for each included study). </p> </div> </div> </div> <section id="CD015254-sec-0064"> <h4 class="title">Allocation</h4> <p>We rated the risk of selection bias as unclear for almost all the studies included in this review. This was due to insufficient detail describing the methods for random allocation to the study groups, and/or a lack of detail regarding methods used to conceal allocation. Only four studies provided a description of adequate randomisation methods (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). Only one of these studies also described appropriate methods to conceal allocation (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>). </p> </section> <section id="CD015254-sec-0065"> <h4 class="title">Blinding</h4> <p>The assessment of performance and detection bias varied across the different studies.</p> <p>We rated a number of studies at high risk of performance bias, as participants would have been aware if they were receiving the active intervention or were in the control group. This included all of the studies for the comparison 'antibiotics versus no treatment' (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>). We rated one further study at high risk of performance bias, as we had concerns over the adequacy of blinding, despite the use of placebo (<a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>). We rated a number of studies as at unclear risk of performance bias ‐ although participants appeared to be blinded to group allocation, it was not clear whether this also extended to study personnel (<a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>). We assessed five studies as having a low risk of performance bias, due to blinding of participants and study personnel (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). </p> <p>Only seven studies indicated that outcome data were collected by blinded assessors, or the outcomes were sufficiently objective that blinding was considered unlikely to impact on the results (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). We rated five studies at high risk of detection bias, as outcome assessors were aware of group allocation (<a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>), and we rated a number of studies at unclear risk for this domain, due to a lack of information on blinding (<a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>). </p> </section> <section id="CD015254-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Most of the studies had complete outcome data for most or all randomised participants, and we therefore considered them at low risk of bias for this domain (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). </p> <p><a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a> and <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a> did not provide details on loss to follow‐up, therefore it was unclear whether there was a risk of bias for this domain. We noted very substantial dropout in the placebo group for the study <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>, leading to imbalance in the groups and the potential for bias. </p> </section> <section id="CD015254-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We rated almost all of the included studies at unclear risk of selective reporting bias, as we were unable to identify a published protocol for the studies and could therefore not compare the reported results to the intended analysis plan. We had specific concerns about three of the included studies, which we rated at high risk of selective reporting. The study <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a> included a narrative report of improvement in OME, but did not provide any data to support this claim. Data included in the study <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> were subsequently reported in a second paper (Cantekin 1991), which identified a different rate of 'cure' for OME, suggesting that there may be a risk of reporting bias. Finally, <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a> assessed hearing outcomes, but presented very limited data, which precluded comparison across the two groups. </p> </section> <section id="CD015254-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We considered that an additional source of bias for many studies was the short duration of follow‐up (three months or less, sometimes as short as 10 days). This would likely be insufficient to expect natural resolution of OME for those who received no treatment or placebo. Consequently, there is a risk that any treatment effect seen in favour of antibiotics may be overestimated. </p> </section> </section> <section id="CD015254-sec-0069"> <h3 class="title" id="CD015254-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD015254-tbl-0001"><b>Summary of findings 1</b> Antibiotics compared to placebo for otitis media with effusion (OME) in children</a>; <a href="./full#CD015254-tbl-0002"><b>Summary of findings 2</b> Antibiotics compared to no treatment for otitis media with effusion (OME) in children</a> </p> <section id="CD015254-sec-0070"> <h4 class="title">Oral antibiotics versus placebo</h4> <p>We identified 11 studies for this comparison (<a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a>; <a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). However, <a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a> did not provide data for any outcomes of interest to this review. </p> <section id="CD015254-sec-0071"> <h5 class="title">Hearing ‐ return to normal hearing</h5> <section id="CD015254-sec-0072"> <h6 class="title">Short‐term follow‐up</h6> <p>A single study considered the number of participants in whom hearing returned to normal after two months of follow‐up. This was reported as the proportion of children in whom the air‐bone gap completely resolved over the follow‐up period. The Peto odds ratio for complete resolution of the air‐bone gap was 9.59 for those receiving antibiotics compared to placebo (95% confidence interval (CI) 3.51 to 26.18; 41% versus 0%; 1 study, 86 participants; <a href="./references#CD015254-fig-0005" title="">Analysis 1.1</a>; very low‐certainty evidence). </p> </section> </section> <section id="CD015254-sec-0073"> <h5 class="title">Hearing ‐ hearing threshold</h5> <section id="CD015254-sec-0074"> <h6 class="title">Short‐term follow‐up</h6> <p>This was assessed by two studies at four weeks, using the speech reception threshold. The mean difference was ‐2.58 dB HL in favour of antibiotics (95% CI ‐4.52 to ‐0.65; 2 studies, 499 participants; I<sup>2</sup> = 0%; <a href="./references#CD015254-fig-0006" title="">Analysis 1.2</a>; low‐certainty evidence). One study presented data from both ears separately for this analysis. We pooled the data, assuming a correlation between ears of 0.5. However, varying this correlation coefficient made very little difference to the overall effect estimates (<a href="./references#CD015254-fig-0007" title="">Analysis 1.3</a>; <a href="./references#CD015254-fig-0008" title="">Analysis 1.4</a>). </p> <p>One study also presented data on speech awareness thresholds, for those children aged under two years, or in whom hearing could not be assessed in other ways. The results were very similar, with a mean difference in hearing level of ‐2.14 dB HL (95% CI ‐5.10 to 0.82; 1 study, 102 participants; <a href="./references#CD015254-fig-0009" title="">Analysis 1.5</a>; very low‐certainty evidence). </p> </section> </section> <section id="CD015254-sec-0075"> <h5 class="title">Disease‐specific quality of life</h5> <p>This outcome was not assessed by any of the included studies.</p> </section> <section id="CD015254-sec-0076"> <h5 class="title">Adverse events ‐ anaphylactic reaction</h5> <p>This outcome was not specifically reported by any of the included studies. See details below regarding generic adverse event reporting. </p> </section> <section id="CD015254-sec-0077"> <h5 class="title">Presence/persistence of OME</h5> <section id="CD015254-sec-0078"> <h6 class="title">Short‐term follow‐up</h6> <p>Nine studies assessed the presence of OME at up to three months follow‐up. The risk ratio (RR) for the persistence of OME in those who received antibiotics was 0.88 (95% CI 0.78 to 1.00; 66% versus 76%; 9 studies, 1375 participants; I<sup>2</sup> = 69%; <a href="./references#CD015254-fig-0010" title="">Analysis 1.6</a>; low‐certainty evidence). </p> <p>We conducted some sensitivity analyses for this result. One study also reported the number of participants with acute otitis (in whom persistence of OME would be difficult to assess). Assuming that these participants also had persistent OME made little difference to the overall result (RR 0.87, 95% CI 0.79 to 0.96; <a href="./references#CD015254-fig-0011" title="">Analysis 1.7</a>). Using different correlation coefficients between ears of the same individual also had almost no impact on the overall results (<a href="./references#CD015254-fig-0012" title="">Analysis 1.8</a>; <a href="./references#CD015254-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD015254-sec-0079"> <h6 class="title">Medium‐term follow‐up</h6> <p>The remaining two studies assessed the presence of OME at 6 to 12 months of follow‐up. The risk ratio for persistence in those receiving antibiotics was 0.89 (95% CI 0.68 to 1.17; 48% versus 54%; 2 studies, 324 participants; I<sup>2</sup> = 32%; <a href="./references#CD015254-fig-0014" title="">Analysis 1.10</a>; very low‐certainty evidence). </p> <p>Again, one study also reported the number of children with acute otitis media without perforation, in whom a diagnosis of persistent OME would have been difficult to assess. Inclusion of these participants in the analysis made a very slight difference to the overall effect estimate (RR 0.93, 95% CI 0.69 to 1.25; <a href="./references#CD015254-fig-0015" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD015254-sec-0080"> <h5 class="title">Adverse events</h5> <p>Adverse events were inconsistently reported across the studies. Data were frequently presented for only one group ‐ those who received the intervention. It was not clear whether this was because no events occurred in the placebo arm, or whether adverse events were not assessed in this group. We have therefore provided a narrative summary of the adverse events that were reported (including gastrointestinal disturbance and rash) in <a href="#CD015254-tbl-0005">Table 3</a>. </p> <div class="table" id="CD015254-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reported data</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Without referring directly to anaphylaxis, 5 trials provided sufficient information to reasonably assume there were no such cases. </p> <p> <ul id="CD015254-list-0040"> <li> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a> and <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a> reported that no participants experienced adverse effects. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that there were no unwanted side effects from the drug (antibiotic) itself. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> did not list anaphylaxis amongst the adverse events that were reported as "probably or possibly related to active treatment". </p> </li> <li> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> reported that "no infant was withdrawn as a result of direct adverse reaction due to medication". </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0041"> <li> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> reported that 1 child amongst 36 (2.8%) who received macrolide antibiotics had vomiting. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> reported vomiting in 3 children of 61 who received cefixime (4.9%), gastroenteritis in 1 (1.6%), stomach pain in 2 (3.3%), loose stools in 2 (3.3%) and diarrhoea in 2 (3.3%). </p> </li> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported that 3 children receiving amoxicillin for 2 weeks had diarrhoea, compared to none of those receiving placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported abdominal cramps, nausea, vomiting, diarrhoea, irritability, nappy rash or combinations of these symptoms, in 3 participants receiving erythromycin‐sulfisoxazole, 4 participants receiving cefaclor, 1 participant receiving amoxicillin and 4 participants receiving placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that 2 of 131 children (1.5%) given amoxicillin‐clavulanate potassium dropped out because of diarrhoea. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> reported that 25 of 79 children who received co‐amoxiclav (30%) developed 'gastrointestinal' side effects, compared to 14 of 74 (18%) who received placebo. The RR was 1.67 (95%CI 0.94 to 2.96) (<a href="./references#CD015254-fig-0017" title="">Analysis 1.13</a>). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rash or irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0042"> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported skin rash in 3 children who had received 2 weeks of amoxicillin, compared to none of those who received placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported urticaria in 2 children receiving cefaclor, 1 of whom also had joint swelling. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that 3 of 131 children (2.3%) given amoxicillin‐clavulanate potassium dropped out because of skin reaction. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> reported that 4 children of 79 who received co‐amoxiclav (5%) developed itching/rash, compared with one of 74 (1.3%) who received placebo. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild sedation, irritability or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0043"> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported that 5% of children who received 2 weeks of amoxicillin and placebo had mild sedation, irritability or both at 2 weeks, compared to 6% of those receiving placebo. The number of children with available data was not reported. At 4 weeks, less than 1.5% in each group reported these symptoms. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported irritability, various gastrointestinal symptoms or combinations of these occurred amongst 3 children receiving erythromycin‐sulfisoxazole, 4 participants receiving cefaclor, 1 participant receiving amoxicillin and 4 participants receiving placebo. The number of children with available data was not reported. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear drum perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0044"> <li> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> reported that 6 of 52 (11.5%) children who received amoxicillin had any perforation (including acute otitis media with perforation, dry perforation or chronic suppurative otitis media) as worst ear status at the end of therapy (up to 24 weeks), compared with 14 of 51 (27.4%) children who received placebo. The RR was 0.42 (95% CI 0.18 to 1.01) (<a href="./references#CD015254-fig-0016" title="">Analysis 1.12</a>). </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </div> <p>Two studies indicated that no adverse events occurred:</p> <p> <ul id="CD015254-list-0045"> <li> <p><a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a> reported that "no adverse events were reported". </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that "no unwanted side effects from the drug" were experienced. </p> </li> </ul> </p> <p><a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a>, <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> and <a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a> did not report on adverse events. It is not clear whether this is because none occurred, or simply because they were not assessed and reported. </p> </section> <section id="CD015254-sec-0081"> <h5 class="title">Receptive language skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0082"> <h5 class="title">Speech development or expressive language skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0083"> <h5 class="title">Cognitive development</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0084"> <h5 class="title">Psychosocial outcomes</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0085"> <h5 class="title">Listening skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0086"> <h5 class="title">Generic health‐related quality of life</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0087"> <h5 class="title">Parental stress</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0088"> <h5 class="title">Vestibular function</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0089"> <h5 class="title">Number of doctor‐diagnosed episodes of acute otitis media</h5> <section id="CD015254-sec-0090"> <h6 class="title">Short‐term follow‐up (up to three months)</h6> <p>Two studies provided information on the number of participants who experienced at least one episode of acute otitis media over four weeks of follow‐up. The risk ratio for acute otitis media was 0.68 for those receiving antibiotics (95% CI 0.42 to 1.10; 9% versus 13%; 2 studies, 615 participants; I<sup>2</sup> = 0%; <a href="./references#CD015254-fig-0018" title="">Analysis 1.14</a>; very low‐certainty evidence). </p> </section> </section> </section> <section id="CD015254-sec-0091"> <h4 class="title">Oral antibiotics versus no treatment</h4> <p>Eight studies were included in this comparison (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>). However, very limited data were available for our outcomes of interest. </p> <section id="CD015254-sec-0092"> <h5 class="title">Hearing ‐ return to normal hearing</h5> <section id="CD015254-sec-0093"> <h6 class="title">Very short‐term follow‐up (&lt; 6 weeks)</h6> <p>A single study assessed the proportion of children whose hearing had "returned to normal thresholds" after 10 days of antibiotic treatment. No definition of normal hearing was provided. The risk ratio was 4.70 in favour of antibiotics (95% CI 1.96 to 11.22; 52% versus 11%; 1 study, 91 participants; <a href="./references#CD015254-fig-0019" title="">Analysis 2.1</a>; very low‐certainty evidence). </p> <p>This outcome was not assessed at later time points.</p> </section> </section> <section id="CD015254-sec-0094"> <h5 class="title">Hearing ‐ hearing threshold</h5> <section id="CD015254-sec-0095"> <h6 class="title">Short‐term follow‐up (up to three months)</h6> <p>Again, this outcome was assessed by a single study. The mean final hearing threshold after three months of follow‐up was ‐5.38 dB HL lower (better) for those who received antibiotics (95% CI ‐9.12 to ‐1.64; 1 study, 73 participants; <a href="./references#CD015254-fig-0020" title="">Analysis 2.2</a>; low‐certainty evidence). </p> <p>This outcome was not assessed at any other time points.</p> </section> </section> <section id="CD015254-sec-0096"> <h5 class="title">Disease‐specific quality of life</h5> <p>This outcome was not assessed by any of the included studies.</p> </section> <section id="CD015254-sec-0097"> <h5 class="title">Adverse events ‐ anaphylactic reaction</h5> <p>This outcome was not specifically reported by any of the included studies. See details below regarding generic adverse event reporting. </p> </section> <section id="CD015254-sec-0098"> <h5 class="title">Presence/persistence of OME</h5> <section id="CD015254-sec-0099"> <h6 class="title">Short‐term follow‐up (up to three months)</h6> <p>Five studies provided data at this time point. Overall, the risk ratio for persistence of OME at up to three months was 0.64 for those receiving antibiotics (95% CI 0.50 to 0.80; 56% versus 87%; 6 studies, 542 participants; I<sup>2</sup> = 72%; <a href="./references#CD015254-fig-0021" title="">Analysis 2.3</a>; low‐certainty evidence). As some data were adjusted to account for potential correlation between ears of the same individual, we conducted a sensitivity analysis to ensure that this did not affect the results. However, the overall effect estimates were similar when using different assumed correlation between the ears of the same individual (<a href="./references#CD015254-fig-0022" title="">Analysis 2.4</a>; <a href="./references#CD015254-fig-0023" title="">Analysis 2.5</a>). </p> <p>No data are available for later time points.</p> </section> </section> <section id="CD015254-sec-0100"> <h5 class="title">Adverse events</h5> <p>We were unable to carry out any meta‐analysis of adverse events, as these were inconsistently reported across the studies. Data from <a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> on the occurrence of vomiting are presented in <a href="#CD015254-tbl-0005">Table 3</a> ‐ this was the only study to report any adverse effects. </p> <p>Two studies indicated that no adverse events occurred:</p> <p> <ul id="CD015254-list-0046"> <li> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a> stated that "No subjects experienced complications during or after the study". </p> </li> <li> <p><a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a> stated, "No medication side effects were reported in any subject". </p> </li> </ul> </p> <p>Five studies did not report adverse events (<a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a>; <a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a>; <a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a>). It is not clear whether this is because none occurred, or simply because they were not assessed and reported. </p> </section> <section id="CD015254-sec-0101"> <h5 class="title">Receptive language skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0102"> <h5 class="title">Speech development or expressive language skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0103"> <h5 class="title">Cognitive development</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0104"> <h5 class="title">Psychosocial outcomes</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0105"> <h5 class="title">Listening skills</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0106"> <h5 class="title">Generic health‐related quality of life</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0107"> <h5 class="title">Parental stress</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0108"> <h5 class="title">Vestibular function</h5> <p>This outcome was not reported by any of the included studies.</p> </section> <section id="CD015254-sec-0109"> <h5 class="title">Number of doctor‐diagnosed episodes of acute otitis media</h5> <section id="CD015254-sec-0110"> <h6 class="title">Short‐term follow‐up (up to three months)</h6> <p>One study assessed this outcome. The proportion of children who experienced one or more episodes of acute otitis media during four weeks of follow‐up was lower in the group who received antibiotics, but the confidence intervals were very wide, and the absolute effect was small (RR 0.40, 95% CI 0.08 to 2.01; 2% versus 5%; 1 study, 196 participants; <a href="./references#CD015254-fig-0024" title="">Analysis 2.6</a>; very low‐certainty evidence). </p> <p>All pre‐specified sensitivity analyses are reported in <a href="#CD015254-tbl-0006">Table 4</a>. </p> <div class="table" id="CD015254-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result (95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antibiotics versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 Hearing threshold: speech reception threshold (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.58 (‐4.52 to ‐0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.58 (‐4.52 to ‐0.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88 (0.78 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies with any concerns over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92 (0.85 to 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88 (0.78 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90 (0.84 to 0.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89 (0.68 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies with any concerns over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.73 to 1.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89 (0.68 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87 (0.70 to 1.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 Episodes of acute otitis media</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (0.42 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (0.42 to 1.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antibiotics versus no treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (0.53 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.50 to 0.86)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; MD: mean difference; OME: otitis media with effusion; RR: risk ratio </p> </div> </div> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015254-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015254-sec-0111"></div> <section id="CD015254-sec-0112"> <h3 class="title" id="CD015254-sec-0112">Summary of main results</h3> <section id="CD015254-sec-0113"> <h4 class="title">Antibiotics compared to placebo</h4> <p>One study provided very low‐certainty evidence of an increase in the proportion of children with normal hearing at two months following antibiotic treatment. Two studies indicated that there may be a small difference in mean final hearing thresholds between those who received antibiotics or placebo, after four weeks of follow‐up. However, we have some concerns regarding the use of mean hearing thresholds to assess hearing in this condition (see below). </p> <p>Persistence of OME after three months of follow‐up may be reduced for those who received antibiotics, compared to placebo. A similar effect size was seen after 6 to 12 months of follow‐up, but the confidence intervals were very wide and included the possibility of no effect. The evidence at this later time point was very uncertain. </p> <p>The evidence on anaphylaxis was very uncertain, as few studies reported specifically on this outcome. However, antibiotics probably increase the risk of gastrointestinal disturbance, and may increase the risk of vomiting, abdominal pain and itching or rash. The evidence was very uncertain for other adverse effects (including diarrhoea and sedation or irritability). </p> <p>The effect of antibiotics compared to placebo on episodes of acute otitis media was very uncertain. </p> </section> <section id="CD015254-sec-0114"> <h4 class="title">Antibiotics compared to no treatment</h4> <p>Similar effects were seen when antibiotics were compared to no treatment. A single study indicated that there may be improvement in the number of children whose hearing returns to normal levels after using antibiotics, but the follow‐up was extremely short (10 days), and the evidence was very uncertain. One other study considered final hearing thresholds after three months of follow‐up, and found that there may be a small mean difference between those who received and did not receive antibiotics. </p> <p>Antibiotics may reduce the proportion of children who have persistent OME after up to three months of follow‐up. It is very uncertain whether the use of antibiotics has an impact on the number of episodes of acute otitis media during three months of follow‐up. The evidence on adverse effects was also very uncertain. We did not identify any evidence on quality of life or developmental outcomes. </p> </section> </section> <section id="CD015254-sec-0115"> <h3 class="title" id="CD015254-sec-0115">Overall completeness and applicability of evidence</h3> <p>Many of the studies included in this review specifically enrolled children who had symptoms of OME for at least three months. Therefore, we do not know whether this treatment may have similar effects in children with a shorter duration of disease. However, this is likely to be the appropriate population, as many practitioners would recommend a period of watchful waiting (to see if the symptoms of OME resolve) before considering any treatment. </p> <p>A wide range of antibiotics were included across the studies in this review. The duration of treatment was also extremely varied, ranging from a 10‐day course of antibiotics up to six months of continuous treatment. We did not have sufficient data to determine if the efficacy (and harms) of different antibiotics or treatment strategies varied. </p> <p>In keeping with other reviews in this suite, we noted that few studies reported our preferred outcome measure for hearing ‐ the number of children who returned to normal hearing. We have concerns that assessment of hearing using the mean difference in final hearing threshold (or mean change in hearing threshold) may not be the most appropriate way to assess hearing. OME has a high spontaneous resolution rate. Consequently, we would anticipate that the change in hearing threshold for most children will be similar across the groups, as many children will improve with or without treatment. Therefore, even if a subset of children had substantial benefit from the intervention, the overall mean difference between the two groups would appear to be small. When assessed using the mean difference, the marked benefit seen in a subgroup of participants is ‘diluted’ by the children who get better regardless of treatment. Therefore, an apparently small mean difference between the two groups may actually be consistent with a substantial change in the number of children in whom hearing returns to normal. </p> <p>Most of the studies included in this review assessed outcomes at the end of the treatment period. However, it is not clear whether any effects seen immediately after discontinuation of antibiotics will persist in the longer term. Importantly, we did not assess whether the use of antibiotics has any impact on the need for further medical treatment, or the requirement for surgery in children with OME. </p> <p>We intended to include studies where children had craniofacial anomalies, or conditions such as Down syndrome. However, the majority of studies specifically excluded children with these conditions (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a>; <a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a>; <a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a>). The remaining studies did not state that children with these conditions were excluded, but none specifically recruited children with these high‐risk conditions. Therefore, we do not know whether the efficacy of antibiotics may differ for these children. </p> <p>We included all studies, regardless of whether participants had previously received other treatment for OME, including ventilation tube insertion. However, we recognise that those who have received additional treatment may represent a subset of children with persistent OME, and that results may not be applicable to all children. </p> </section> <section id="CD015254-sec-0116"> <h3 class="title" id="CD015254-sec-0116">Quality of the evidence</h3> <p>We considered the certainty of all the evidence to be low or very low. Many of the studies had significant concerns or lack of clarity regarding the risk of bias. The majority of studies failed to give sufficient information on their randomisation and allocation concealment, therefore we had concerns over the possibility of differences in confounding variables between the two groups. We also had concerns about some studies regarding the potential for performance or detection bias, as participants, study personnel and outcome assessors were not always blinded to the group allocation. </p> <p>Although we included 19 studies, many considered only a few of our pre‐specified outcomes of interest. Outcomes were also reported at a variety of time points, precluding meaningful meta‐analysis. Consequently, the number of participants included in many of the analyses was small, leading to wide confidence intervals and imprecision in the estimated effects. </p> </section> <section id="CD015254-sec-0117"> <h3 class="title" id="CD015254-sec-0117">Potential biases in the review process</h3> <p>We have attempted to minimise the potential for bias during the review process by adhering to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> throughout the conduct of this review (<a href="./references#CD015254-bbs2-0080" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). We conducted comprehensive searches, and ensured that study selection, data extraction and GRADE assessment were carried out by at least two independent authors, to ensure reproducibility of findings. </p> <p>We acknowledge that there is little consensus on the definition of 'normal hearing'. Consequently, our selection of a hearing threshold of ≤ 20 dB HL as 'normal' was based on discussion between the author team, review of earlier studies and a pragmatic choice of outcome measure. However, we were as inclusive as possible with this outcome measure, and have included data where authors provided an alternative definition of normal hearing. If we had rigidly used a definition of ≤ 20 dB HL then the data included in this review would have been even more sparse. </p> </section> <section id="CD015254-sec-0118"> <h3 class="title" id="CD015254-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>The previous Cochrane Review on this topic came to similar conclusions ‐ that antibiotics may increase the resolution of OME, but the impact on hearing was uncertain, and they can be associated with adverse effects (<a href="./references#CD015254-bbs2-0119" title="VenekampRP , BurtonMJ , vanDongenTMA , van derHeijdenGJ , vanZonA , SchilderAGM . Antibiotics for otitis media with effusion in children. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009163. [DOI: 10.1002/14651858.CD009163.pub3]">Venekamp 2016</a>). It should be noted that the previous review also included a number of trials that compared antibiotics to medical interventions (including antihistamines, decongestants, mucolytics and intranasal corticosteroids). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015254-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-FIG-01" target="_blank"><b></b></a></p> </div><img alt="The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool" data-id="CD015254-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>The Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-FIG-02" target="_blank"><b></b></a></p> </div><img alt="A flow chart of study retrieval and selection." data-id="CD015254-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>A flow chart of study retrieval and selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies)." data-id="CD015254-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph (our judgements about each risk of bias item presented as percentages across all included studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary (our judgements about each risk of bias item for each included study)." data-id="CD015254-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary (our judgements about each risk of bias item for each included study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 1: Normal hearing (as complete improvement in air‐bone gap in worst ear): short‐term" data-id="CD015254-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 1: Normal hearing (as complete improvement in air‐bone gap in worst ear): short‐term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 2: Hearing threshold: speech reception threshold (short‐term). Correction of variance assuming correlation coefficient of 0.5" data-id="CD015254-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 2: Hearing threshold: speech reception threshold (short‐term). Correction of variance assuming correlation coefficient of 0.5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 3: Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3" data-id="CD015254-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 3: Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 4: Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7" data-id="CD015254-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 4: Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 5: Hearing threshold: speech awareness threshold (short‐term)" data-id="CD015254-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 5: Hearing threshold: speech awareness threshold (short‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 6: Persistence of OME (short‐term)" data-id="CD015254-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 6: Persistence of OME (short‐term)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 7: Sensitivity analysis: persistence (short‐term) including cases of acute otitis (Mandel 1987)" data-id="CD015254-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 7: Sensitivity analysis: persistence (short‐term) including cases of acute otitis (Mandel 1987) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 8: Sensitivity analysis: persistence (short‐term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985)" data-id="CD015254-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 8: Sensitivity analysis: persistence (short‐term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 9: Sensitivity analysis: persistence (short‐term) assuming ICC of zero (no correlation between ears) (Puhakka 1985)" data-id="CD015254-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 9: Sensitivity analysis: persistence (short‐term) assuming ICC of zero (no correlation between ears) (Puhakka 1985) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 10: Persistence of OME (medium‐term)" data-id="CD015254-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 10: Persistence of OME (medium‐term)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (medium‐term); defined as 'OME' or 'AOM without perforation' (Leach 2008)" data-id="CD015254-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 11: Sensitivity analysis: persistence of OME (medium‐term); defined as 'OME' or 'AOM without perforation' (Leach 2008) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 12: Adverse event: eardrum perforation" data-id="CD015254-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 12: Adverse event: eardrum perforation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 13: Adverse event: 'gastrointestinal'" data-id="CD015254-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 13: Adverse event: 'gastrointestinal'</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotic versus placebo, Outcome 14: Episodes of acute otitis media" data-id="CD015254-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Antibiotic versus placebo, Outcome 14: Episodes of acute otitis media</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 1: Hearing returned to normal (very short‐term)" data-id="CD015254-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 1: Hearing returned to normal (very short‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 2: Final hearing threshold (short‐term)" data-id="CD015254-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 2: Final hearing threshold (short‐term)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 3: Persistence of OME (short‐term)" data-id="CD015254-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 3: Persistence of OME (short‐term)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 4: Sensitivity analysis 1: persistence of OME (short‐term). ICC = zero" data-id="CD015254-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 4: Sensitivity analysis 1: persistence of OME (short‐term). ICC = zero </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 5: Sensitivity analysis 2: persistence of OME (short‐term). ICC = 1.0" data-id="CD015254-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 5: Sensitivity analysis 2: persistence of OME (short‐term). ICC = 1.0 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015254-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/urn:x-wiley:14651858:media:CD015254:CD015254-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotic versus no treatment, Outcome 6: Episodes of acute otitis media (short‐term)" data-id="CD015254-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_t/tCD015254-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Antibiotic versus no treatment, Outcome 6: Episodes of acute otitis media (short‐term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/media/CDSR/CD015254/image_n/nCD015254-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015254-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics compared to placebo for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antibiotics compared to placebo for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children (aged 6 months to 12 years) with otitis media with effusion (OME)<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral antibiotics <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral antibiotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Hearing ‐ return to normal hearing</b> (as complete improvement in air‐bone gap in the worst ear) </p> <p>Follow‐up: 2 months (short‐term)</p> <p>№ of participants: 86<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>Peto OR 9.59<br/>(3.51 to 26.18) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Lower‐risk population*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>The evidence is very uncertain about the effect of antibiotics on return to normal hearing at 2 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5%<br/>(15.6 to 57.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.5% more<br/>(10.6 more to 52.9 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Moderate‐risk population*</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.2%<br/>(30.3 to 76.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2% more<br/>(19.3 more to 65.4 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Higher‐risk population*</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9%<br/>(38.2 to 82.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9% more<br/>(23.2 more to 67.2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease‐specific quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No evidence was identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Presence/persistence of OME</b> </p> <p>Follow‐up: range 6 months to 12 months (medium‐term)</p> <p>№ of participants: 324 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.68 to 1.17) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of antibiotics on persistence of OME at 6 to 12 months, when compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1%<br/>(36.7 to 63.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9% fewer<br/>(17.3 fewer to 9.2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event: anaphylaxis</b> </p> <p>Follow‐up: range 3 weeks to 12 months</p> <p>№ of participants: 244 (3 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Three trials that did not report the incidence of anaphylaxis directly did, however, provide sufficient information to reasonably assume there were no such cases. One trial reported that there were no unwanted side effects from the drug (antibiotic) itself (<a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>); one trial did not list anaphylaxis amongst adverse events that were reported as "probably or possibly related to active treatment" (<a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>); and one trial reported that "no infant was withdrawn as a result of direct adverse reaction due to medication" (<a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of anaphylaxis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where there were zero events in the comparison group, the assumed risk in the comparison group was imputed from the same outcome comparing antibiotic with no treatment (<a href="./full#CD015254-tbl-0002">summary of findings Table 2</a>). This value was assumed to represent a 'moderate' control group event rate (CER), and values roughly 50% lower and higher are presented as 'lower' and 'higher' CERs respectively. </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for risk of performance detection and attrition bias. Downgraded by one level for imprecision as the optimal information size was not reached (&lt; 300 events). </p> <p><sup>2</sup>Downgraded by one level for risk of bias, due to the potential for underestimating the prevalence of OME at six months. Participants with two normal examinations at &lt; 6 months were not re‐assessed, but were considered to have resolution of OME. Downgraded by one level for inconsistency, as the studies showed opposite directions of effect. Downgraded by one level for indirectness, as a high‐risk population of children aged &lt; 12 months contributed most of the weight in the analysis. Downgraded by one level for serious imprecision, as the optimal information size was not reached (&lt; 300 events) and one decision threshold was crossed by the confidence interval (RR 0.80). </p> <p><sup>3</sup>Downgraded by three levels for extremely serious imprecision, as this was a narrative synthesis with zero events amongst 244 participants. We are unable to provide an estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics compared to placebo for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015254-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics compared to no treatment for otitis media with effusion (OME) in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antibiotics compared to no treatment for otitis media with effusion (OME) in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> children (aged 6 months to 12 years) with otitis media with effusion (OME) <br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> oral antibiotics <br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Without oral antibiotic</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With oral antibiotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hearing ‐ hearing threshold</b><sup>‡</sup> (3 months; short‐term) </p> <p>№ of participants: 73 (1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final hearing threshold was 14.1 dB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.38 dB lower<br/>(9.12 lower to 1.64 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that antibiotics result in little to no difference in hearing threshold at 3 months when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐specific quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No evidence was identified for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Presence/persistence of OME</b> (up to 3 months) </p> <p>№ of participants: 542 (6 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.50 to 0.80) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9%</p> <p>(43.7 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5% fewer (from 43.7 fewer to 17.5 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics may reduce the proportion of children with persistent OME at up to 3 months when compared with no treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event: anaphylaxis</b> </p> <p>Follow‐up: range 2 months to 3 months</p> <p>№ of participants: 88 (2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Without referring directly to anaphylaxis, two studies reported that no participants experienced adverse effects (<a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>). It is unlikely, therefore, that any participants experienced anaphylaxis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the risk of anaphylaxis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>‡</sup>Note that additional data were available for the outcome 'Hearing ‐ return to normal hearing'. However, as the follow‐up duration was extremely short (10 days), we did not consider it meaningful to present these data in the summary of findings table. </p> <p><sup>1</sup>Downgraded by one level for a risk of performance bias. Downgraded by one level for serious imprecision as the optimal information size (OIS) was not reached (&lt; 400 participants). </p> <p><sup>2</sup>Downgraded by two levels for risk of performance and detection bias. Not downgraded for imprecision, as there was a common direction of effect, despite some inconsistency (I<sup>2</sup> = 72%). </p> <p><sup>3</sup>Downgraded by three levels for extremely serious imprecision, as this was a narrative synthesis with no events reported amongst only 88 children. No estimate of effect size could be calculated. We did not downgrade for risk of bias, as this is an objective outcome, unlikely to be influenced by performance bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics compared to no treatment for otitis media with effusion (OME) in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015254-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Possible RCTs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rejected</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Known assessments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT classifier</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1514</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cochrane Crowd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1313</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2877</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>RCT: randomised controlled trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs identified through Cochrane Crowd and the RCT classifier</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015254-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison of studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up (main outcomes reported at this time)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with chronic OME (≥ 3 months), without response to 3 courses of antibiotics (n = 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐amoxiclav, 40 mg/kg/day in 3 divided doses for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A third arm received anti‐reflux medication, but this was not relevant to this review, therefore data were not extracted </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0002" title="BalleVH , StangerupSE , Sederberg-OlsenJ , ThomsenJ , VejlsgaardR . Amoxicillin/clavulanate treatment in secretory otitis media. Bacteriological findings in the nasopharynx. Acta Oto-laryngologica1990;110(3-4):274-8. [CENTRAL: CN-00071274] [PMID: 2239218]">Balle 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with at least 3 months duration of uni‐ or bilateral OME (n = 264) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study conducted in Denmark. No details on participant recruitment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks treatment with amoxicillin and clavulanate potassium. Concentration not stated. Children aged 1 to 5 had 5 mL 3 times daily, children aged 6 to 10 had 7.5 mL 3 times daily. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this study did not provide any data for outcomes of interest in this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 3 to 14 years with OME for less than 3 months (n = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre, university ENT department in China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 15 mg/kg/day in 2 divided doses for 1 week, then 5 to 8 mg/kg/day until the tympanogram was type A (range of treatment 5 to 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical glucocorticoid spray was given to all participants for 12 weeks</p> <p>It appears that all participants underwent tympanocentesis at the start of the trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two children in the intervention group actually received azithromycin, instead of clarithromycin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0004" title="EndoLH , AntunesAB , VidolinC , BileckiMM , MagalhaesKVB . Secretory media otitis: clinical treatment vs placebo [Otite media secretora: tratamento clinco versus placebo]. Revista Brasileira de Otorrinolaringologia1997;63(2):116-9. [CENTRAL: CN-00316174] ">Endo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with bilateral OME, aged less than 2 years (n = 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxazole‐trimethoprim 20 mg/kg/day in a single night‐time dose for 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stated to be placebo, but no information on the nature of the placebo is provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this trial also included older children, but they received a different intervention, not relevant for this review </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0005" title="ErnstsonS , AnariM . Cefaclor in the treatment of otitis media with effusion. Acta Oto-laryngologica. Supplementum1985;424:17-21. [CENTRAL: CN-00040675] [PMID: 3865493]">Ernston 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &lt; 12 years with uni‐ or bilateral OME for at least 3 months (n = 91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cefaclor 20 mg/kg twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0006" title="HealyGB . Antimicrobial therapy of chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology1984;8(1):13-7. [CENTRAL: CN-00036115] [PMID: 6389394]">Healy 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 5 years with OME for ≤ 6 weeks (n = 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre, university hospital study from USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trimethoprim‐sulfamethoxazole (8 mg and 40 mg/kg/day respectively) in 2 divided doses for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with uni‐ or bilateral OME for at least 3 months (n = 81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cefixime 8 mg/kg per day in 2 divided doses for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suspension of similar appearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that a third arm received antibiotics and steroids. Data are not relevant for this review, so have not been included here. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0008" title="KarlidagT , KaygusuzI , GokU , YalcinS , KelesE , OzturkL . The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion [Efuzyonlu otitis media tedavisinde antibiyotik ile birlikte intranazal steroid kullaniminin etkinligi]. Kulak Burun Bogaz Ihtisas Dergisi: KBB [Journal of Ear, Nose, and Throat]2002;9(4):257-62. [CENTRAL: CN-00411239] [PMID: 12422079]">Karlidag 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 12 years with uni‐ or bilateral OME (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ampicillin/sulbactam 25 mg/kg/day, in 2 divided doses for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that a third arm received antibiotics and steroids. Data are not relevant for this review, so have not been included here. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aboriginal infants aged &lt; 12 months with OME (n = 103)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruited from 3 Aboriginal communities in Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 24 weeks, or until bilateral normal middle ear status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo suspension of equivalent volume</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 12 years with OME (n = 340)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 40 mg/kg per day in 3 divided doses for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups also received an additional placebo for the third arm of this study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A third treatment arm received antibiotics and antihistamine. Data were not relevant for this review, therefore not included. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 12 years with OME (n = 331)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin and sulfisoxazole (50 mg and 150 mg/kg/day respectively) in 4 divided doses for 2 weeks </p> <p>or</p> <p>Cefaclor 40 mg/kg/day in 3 divided doses for 2 weeks</p> <p>or</p> <p>Amoxicillin 40 mg/kg/day in 3 divided doses for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that data from all of the arms receiving antibiotics have been pooled for the purposes of analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0012" title="ManriqueMJ , HernándezJ , HuarteA , RiveraR , García-TapiaR . Treatment of secretory otitis media with Ambroxol [Tratamiento de la otitis serosa con Ambroxol]. Acta Pediatrica Española1987;45(1):17-20. ">Manrique 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 8 months to 13 years with unilateral or bilateral OME for at least 3 months (52 ears assessed, number of children unclear) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in both groups received a daily dose of a decongestant syrup (chlorhydrate ambroxol, dose dependent on age) for the duration of the trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 7 years with OME for at least 3 months (n = 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre study from Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceftibuten 9 mg/kg/day in 1 daily dose for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (nasal saline drops)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0014" title="MollerP , DingsorG . Otitis media with effusion: can erythromycin reduce the need for ventilating tubes?Journal of Laryngology and Otology1990;104(3):200-2. [CENTRAL: CN-00067688] [PMID: 2341774]">Møller 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 15 years with bilateral OME for at least 3 months, awaiting ventilation tube insertion (n = 147) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin 50 mg/kg/day in 2 divided doses for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0015" title="PodoshinL , FradisM , Ben-DavidY , FaraggiD . The efficacy of oral steroids in the treatment of persistent otitis media with effusion. Archives of Otolaryngology-Head &amp; Neck Surgery1990;116(12):1404-6. [CENTRAL: CN-00071613] [PMID: 2248740]">Podoshin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 4 to 8 years with OME for ≥ 2 months, who had received no previous treatment (n = 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Israel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 50 mg/kg/day for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lactose powder placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received an additional placebo to account for the third intervention in this study (antibiotics plus prednisone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that there was a third arm in this study, where participants received both antibiotics and steroids. Data have not been extracted for this review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0016" title="PuhakkaH , HaapaniemiJ , TuohimaaP , RuuskanenO , EskolaJ . Peroral prednisolone in the treatment of middle-ear effusion in children: a double-blind study. Auris, Nasus, Larynx1985;12 Suppl 1:S268-71. [CENTRAL: CN-00043250] [EMBASE: 16731329] [PMID: 3915207]">Puhakka 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 7 months to 11 years with OME (n = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg trimethoprim and 18.5 mg sulfadiazine/kg/day in 2 divided doses for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups received an additional placebo to account for the third intervention in this study (antibiotics plus prednisone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that there was a third arm in this study, where participants received both antibiotics and steroids. Data have not been extracted for this review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0017" title="SundbergL , CederbergA , EdenT , ErnstsonS . The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media. Acta Oto-Laryngologica1984;97(3-4):379-83. ">Sundberg 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1.5 to 11 years with unilateral or bilateral OME for at least 3 months (n = 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin ethylsuccinate 20 to 30 mg/kg twice daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that this study did not provide any data for outcomes of interest in this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years with at least 3 months of unilateral or bilateral OME (n = 264) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin and clavulanate potassium with 125 mg/31.25 mg 3 times daily (if aged 1 to 5) or 187 mg/46.9 mg 3 times daily (if aged 6 to 10) for 1 month </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In patients with bilateral disease, a ventilation tube was inserted in the right ear, and the left ear was included in the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged ≤ 6 years with at least 3 months of OME (n = 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐centre study from the Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin 20 mg/kg/day plus 5 mg/kg/day clavulanic acid in 3 divided doses for 14 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One drop of decongestant (oxymetazoline 0.25%) 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>OME: otitis media with effusion</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015254-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reported data</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a>; <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Without referring directly to anaphylaxis, 5 trials provided sufficient information to reasonably assume there were no such cases. </p> <p> <ul id="CD015254-list-0040"> <li> <p><a href="./references#CD015254-bbs2-0001" title="ArdehaliMM , SerajJM , AsiabarMK , AdibiH . The possible role of gastroesophageal reflux disease in children suffering from chronic otitis media with effusion. Acta Medica Iranica2008;46(1):33-7. [CENTRAL: CN-00708224] [EMBASE: 351792703]">Ardehali 2008</a> and <a href="./references#CD015254-bbs2-0013" title="MarchisioP , PrincipiN , PassaliD , SalpietroDC , BoschiG , ChetrìG , et al. Epidemiology and treatment of otitis media with effusion in children in the first year of primary school. Acta Oto-Laryngologica1998;118(4):557-62. [CENTRAL: CN-00154484] [EMBASE: 1998254893] [PMID: 9726683]">Marchisio 1998</a> reported that no participants experienced adverse effects. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that there were no unwanted side effects from the drug (antibiotic) itself. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> did not list anaphylaxis amongst the adverse events that were reported as "probably or possibly related to active treatment". </p> </li> <li> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> reported that "no infant was withdrawn as a result of direct adverse reaction due to medication". </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a>; <a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a>; <a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0041"> <li> <p><a href="./references#CD015254-bbs2-0003" title="ChenK , WuX , JiangG , DuJ , JiangH . Low dose macrolide administration for long term is effective for otitis media with effusion in children. Auris, Nasus, Larynx2013;40(1):46-50. [CENTRAL: CN-00880075] [PMID: 22673738]">Chen 2013</a> reported that 1 child amongst 36 (2.8%) who received macrolide antibiotics had vomiting. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0007" title="HemlinC , CarenfeltC , PapatziamosG . Single dose of betamethasone in combined medical treatment of secretory otitis media. Annals of Otology, Rhinology, and Laryngology1997;106(5):359-63. [CENTRAL: CN-00139646] [PMID: 9153098]PapatziamosG , HemlinC , CarenfeltC . Recent Advances in Otitis Media. Kugler Publications, Amsterdam/New York, 1994. ">Hemlin 1997</a> reported vomiting in 3 children of 61 who received cefixime (4.9%), gastroenteritis in 1 (1.6%), stomach pain in 2 (3.3%), loose stools in 2 (3.3%) and diarrhoea in 2 (3.3%). </p> </li> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported that 3 children receiving amoxicillin for 2 weeks had diarrhoea, compared to none of those receiving placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported abdominal cramps, nausea, vomiting, diarrhoea, irritability, nappy rash or combinations of these symptoms, in 3 participants receiving erythromycin‐sulfisoxazole, 4 participants receiving cefaclor, 1 participant receiving amoxicillin and 4 participants receiving placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that 2 of 131 children (1.5%) given amoxicillin‐clavulanate potassium dropped out because of diarrhoea. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> reported that 25 of 79 children who received co‐amoxiclav (30%) developed 'gastrointestinal' side effects, compared to 14 of 74 (18%) who received placebo. The RR was 1.67 (95%CI 0.94 to 2.96) (<a href="./references#CD015254-fig-0017" title="">Analysis 1.13</a>). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rash or irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a>; <a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a>; <a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a>; <a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0042"> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported skin rash in 3 children who had received 2 weeks of amoxicillin, compared to none of those who received placebo. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported urticaria in 2 children receiving cefaclor, 1 of whom also had joint swelling. The number of children with available data was not reported. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0018" title="ThomsenJ , Sederberg-OlsenJ , BalleV , VejlsgaardR , StangerupSE , BondessonG . Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study. Archives of Otolaryngology-Head &amp; Neck Surgery1989;115(4):447-51. [CENTRAL: CN-00058572] [PMID: 2647105]ThomsenJ , Sederberg-OlsenJ , StangerupSE , BalleV , VejlsgaardR . Long-term antibiotic treatment of children with secretory otitis media: a double-blind placebo-controlled study. Acta Oto-Laryngologica. Supplementum1988;449:49-50. [CENTRAL: CN-00056944] [PMID: 3059752]">Thomsen 1989</a> reported that 3 of 131 children (2.3%) given amoxicillin‐clavulanate potassium dropped out because of skin reaction. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0019" title="vanBalenFA , deMelkerRA , Touw-OttenFW . Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet1996;348(9029):713-6. [CENTRAL: CN-00129985] [EMBASE: 1996280110] [PMID: 8806290]">van Balen 1996</a> reported that 4 children of 79 who received co‐amoxiclav (5%) developed itching/rash, compared with one of 74 (1.3%) who received placebo. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild sedation, irritability or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0043"> <li> <p><a href="./references#CD015254-bbs2-0010" title="CantekinEI , McGuireTW , GriffithTL . Antimicrobial therapy for otitis media with effusion ('secretory' otitis media). JAMA1991;266(23):3309-17. [CENTRAL: CN-00079882] [PMID: 1683673]MandelEM , RocketteHE , BluestoneCD , ParadiseJL , NozzaRJ . Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. New England Journal of Medicine1987;316(8):432-7. [CENTRAL: CN-00046384] [PMID: 2880294]">Mandel 1987</a> reported that 5% of children who received 2 weeks of amoxicillin and placebo had mild sedation, irritability or both at 2 weeks, compared to 6% of those receiving placebo. The number of children with available data was not reported. At 4 weeks, less than 1.5% in each group reported these symptoms. </p> </li> <li> <p><a href="./references#CD015254-bbs2-0011" title="MandelEM , RocketteHE , ParadiseJL , BluestoneCD , NozzaRJ . Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatric Infectious Disease Journal1991;10(12):899-906. [CENTRAL: CN-00080817] [PMID: 1766705]">Mandel 1991</a> reported irritability, various gastrointestinal symptoms or combinations of these occurred amongst 3 children receiving erythromycin‐sulfisoxazole, 4 participants receiving cefaclor, 1 participant receiving amoxicillin and 4 participants receiving placebo. The number of children with available data was not reported. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ear drum perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD015254-list-0044"> <li> <p><a href="./references#CD015254-bbs2-0009" title="LeachAJ , MorrisPS , MathewsJD , HayhurstB , KoopsH , MelderA , et al. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatrics2008;8:23. [CENTRAL: CN-00639992] [EMBASE: 2008359321] [PMID: 18513453]NCT00539149. Long-term antibiotics for treatment and prevention of otitis media in aborignal children [Amoxycillin versus placebo for resolution of otitis media with effusion and prevention of acute otitis media with perforation in aboriginal infants: a randomised controlled trial]. https://clinicaltrials.gov/show/NCT00539149 (first received 4 October 2007). [CENTRAL: CN-00652606] ">Leach 2008</a> reported that 6 of 52 (11.5%) children who received amoxicillin had any perforation (including acute otitis media with perforation, dry perforation or chronic suppurative otitis media) as worst ear status at the end of therapy (up to 24 weeks), compared with 14 of 51 (27.4%) children who received placebo. The RR was 0.42 (95% CI 0.18 to 1.01) (<a href="./references#CD015254-fig-0016" title="">Analysis 1.12</a>). </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015254-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis result (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis result (95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antibiotics versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 Hearing threshold: speech reception threshold (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.58 (‐4.52 to ‐0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.58 (‐4.52 to ‐0.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88 (0.78 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies with any concerns over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92 (0.85 to 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88 (0.78 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90 (0.84 to 0.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89 (0.68 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies with any concerns over trustworthiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.73 to 1.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 Persistence of OME (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89 (0.68 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87 (0.70 to 1.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 Episodes of acute otitis media</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (0.42 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (0.42 to 1.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antibiotics versus no treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (0.53 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 Persistence of OME (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exclusion of studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.50 to 0.86)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; MD: mean difference; OME: otitis media with effusion; RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/full#CD015254-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015254-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Normal hearing (as complete improvement in air‐bone gap in worst ear): short‐term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.59 [3.51, 26.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Hearing threshold: speech reception threshold (short‐term). Correction of variance assuming correlation coefficient of 0.5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐4.52, ‐0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐4.38, ‐0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐4.64, ‐0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Hearing threshold: speech awareness threshold (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Persistence of OME (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Persistence defined as effusion in one ear or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Persistence defined as effusion both ears if bilateral at baseline, and in one/both ears if unilateral </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Sensitivity analysis: persistence (short‐term) including cases of acute otitis (Mandel 1987) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.79, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Persistence defined as effusion in one ear or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Persistence defined as effusion in both ears (if bilateral at baseline) and in one or both ears (if unilateral) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Sensitivity analysis: persistence (short‐term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Persistence defined as effusion in one ear or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Persistence defined as effusion in both ears (if bilateral at baseline) and in one or both ears (if unilateral) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Sensitivity analysis: persistence (short‐term) assuming ICC of zero (no correlation between ears) (Puhakka 1985) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Persistence defined as effusion in one ear or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Persistence defined as effusion in both ears (if bilateral at baseline) and in one or both ears (if unilateral) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Persistence defined as effusion in the worst ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Persistence of OME (medium‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Persistence defined as 'OME' in one or both affected ears</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.73, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Persistence defined as effusion in affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Sensitivity analysis: persistence of OME (medium‐term); defined as 'OME' or 'AOM without perforation' (Leach 2008) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Persistence defined as 'OME or AOM without perforation' in one or both affected ears </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.85, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Persistence defined as effusion in affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse event: eardrum perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.18, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse event: 'gastrointestinal' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Episodes of acute otitis media <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.42, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015254-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antibiotic versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Hearing returned to normal (very short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.70 [1.96, 11.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Final hearing threshold (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.38 [‐9.12, ‐1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Persistence of OME (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.50, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Analysis by child: persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Analysis by child: persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Analysis by ear. Adjusted for non‐independence, assuming ICC of 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.64, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Sensitivity analysis 1: persistence of OME (short‐term). ICC = zero <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.50, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Analysis by child: persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Analysis by child: persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Analysis by ear. Adjusted for non‐independence, assuming ICC of 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Sensitivity analysis 2: persistence of OME (short‐term). ICC = 1.0 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.50, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Analysis by child: persistence in any ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Analysis by child: persistence in any affected ear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Analysis by ear. Adjusted for non‐independence, assuming ICC of 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Episodes of acute otitis media (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antibiotic versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015254.pub2/references#CD015254-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015254.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015254-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015254-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015254-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015254-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015254-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD015254-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD015254-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015254-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015254-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015254\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015254\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015254\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015254\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015254\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015254.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015254.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015254.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015254.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015254.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716931388"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015254.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716931392"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015254.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dab8d1becf3f1',t:'MTc0MDcxNjkzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 